Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
22,800 | 2023-02-09 00:00:00 UTC | US STOCKS-Wall St dips as Treasury yields rise; Disney hits 5-month high | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-st-dips-as-treasury-yields-rise-disney-hits-5-month-high | null | null | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
Disney jumps on Q1 beat, layoff plans
PepsiCo gains on quarterly profit, sales beat
Salesforce rises on reports Third Point owns stake
U.S. weekly jobless claims increase
Dow down 0.52%, S&P 500 down 0.56%, Nasdaq... | PepsiCo Inc PEP.O rose 0.67% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 3.08% after beating fourth-quarter profit expectations. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Disney jumps on Q... | PepsiCo Inc PEP.O rose 0.67% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 3.08% after beating fourth-quarter profit expectations. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Disney jumps on Q... | PepsiCo Inc PEP.O rose 0.67% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 3.08% after beating fourth-quarter profit expectations. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Disney jumps on Q... | PepsiCo Inc PEP.O rose 0.67% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 3.08% after beating fourth-quarter profit expectations. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Disney jumps on Q... |
22,801 | 2023-02-09 00:00:00 UTC | US STOCKS-Wall St dips as Alphabet extends fall; Disney hits 5-month high | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-st-dips-as-alphabet-extends-fall-disney-hits-5-month-high | null | null | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
Disney jumps on Q1 beat, layoff plans
PepsiCo gains on quarterly profit, sales beat
Salesforce rises on reports Third Point owns stake
U.S. weekly jobless claims increase
Indexes down: Dow 0.22%, S&P 0.24%, Nasdaq... | PepsiCo Inc PEP.O rose 1.2% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 3.1% after beating fourth-quarter profit expectations. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Disney jumps on Q1 ... | PepsiCo Inc PEP.O rose 1.2% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 3.1% after beating fourth-quarter profit expectations. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Disney jumps on Q1 ... | PepsiCo Inc PEP.O rose 1.2% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 3.1% after beating fourth-quarter profit expectations. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Disney jumps on Q1 ... | PepsiCo Inc PEP.O rose 1.2% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 3.1% after beating fourth-quarter profit expectations. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Disney jumps on Q1 ... |
22,802 | 2023-02-09 00:00:00 UTC | What Stocks to Buy Today? 3 Dividend Stocks To Watch After Earnings | ABBV | https://www.nasdaq.com/articles/what-stocks-to-buy-today-3-dividend-stocks-to-watch-after-earnings | null | null | Dividends are payments made by a corporation to its shareholders. They are typically in the form of cash or additional shares of stock. They are a way for companies to reward their investors for holding their stock. As such, they can provide a steady source of income for investors. Dividend stocks are stocks that pay d... | Dividend Stocks To Watch For February 2023 PepsiCo, Inc. (NASDAQ: PEP) AbbVie Inc. (NYSE: ABBV) Philip Morris International Inc. (NYSE: PM) PepsiCo (PEP Stock) To kick us off, PepsiCo, Inc. (PEP) is a multinational food and beverage company that offers a wide range of products, including beverages, snacks, and breakfas... | Dividend Stocks To Watch For February 2023 PepsiCo, Inc. (NASDAQ: PEP) AbbVie Inc. (NYSE: ABBV) Philip Morris International Inc. (NYSE: PM) PepsiCo (PEP Stock) To kick us off, PepsiCo, Inc. (PEP) is a multinational food and beverage company that offers a wide range of products, including beverages, snacks, and breakfas... | Dividend Stocks To Watch For February 2023 PepsiCo, Inc. (NASDAQ: PEP) AbbVie Inc. (NYSE: ABBV) Philip Morris International Inc. (NYSE: PM) PepsiCo (PEP Stock) To kick us off, PepsiCo, Inc. (PEP) is a multinational food and beverage company that offers a wide range of products, including beverages, snacks, and breakfas... | Dividend Stocks To Watch For February 2023 PepsiCo, Inc. (NASDAQ: PEP) AbbVie Inc. (NYSE: ABBV) Philip Morris International Inc. (NYSE: PM) PepsiCo (PEP Stock) To kick us off, PepsiCo, Inc. (PEP) is a multinational food and beverage company that offers a wide range of products, including beverages, snacks, and breakfas... |
22,803 | 2023-02-09 00:00:00 UTC | AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-beats-q4-earnings-estimates-misses-on-sales | null | null | AbbVie Inc. ABBV reported adjusted earnings of $3.60 per share for the fourth quarter of 2022, beating both the Zacks Consensus Estimate and our estimate, which stood at $3.54. The reported earnings also exceeded the guidance of $3.51-$3.55. Earnings rose 16.9% year over year.
ABBV’s revenues of $15.12 billion missed t... | Amgen, Biogen, Boehringer Ingelheim, Pfizer, Sandoz and many other companies have already received FDA approvals for their own Humira biosimilars, many of which are expected to be launched at various times this year per agreements with AbbVie. Juvederm sales were hurt by the impact of COVID in China and the suspension ... | AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales declined 11.2% on an operational basis to $1.63 billion in the quarter, as growth of Venclexta sales, was more than offset by lower U.S. sales of Imbruvica. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Johnson & John... | AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales declined 11.2% on an operational basis to $1.63 billion in the quarter, as growth of Venclexta sales, was more than offset by lower U.S. sales of Imbruvica. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Johnson & John... | AbbVie’s share of profit from the international sales of the J&J-partnered drug rose 1.6% to $274 million. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Ana... |
22,804 | 2023-02-09 00:00:00 UTC | Vanguard Group Increases Position in AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/vanguard-group-increases-position-in-abbvie-abbv | null | null | Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 158.32MM shares of AbbVie Inc (ABBV). This represents 8.95% of the company.
In their previous filing dated February 9, 2022 they reported 146.31MM shares and 8.28% of the company, an increase in shares of 8.21% and an increas... | Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 158.32MM shares of AbbVie Inc (ABBV). AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Analyst Price Forecast Suggests 14.... | Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 158.32MM shares of AbbVie Inc (ABBV). Analyst Price Forecast Suggests 14.89% Upside As of February 9, 2023, the average one-year price target for AbbVie is $166.14. The projected annual revenue for AbbVie is $55,229MM, a decr... | Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 158.32MM shares of AbbVie Inc (ABBV). Analyst Price Forecast Suggests 14.89% Upside As of February 9, 2023, the average one-year price target for AbbVie is $166.14. The projected annual revenue for AbbVie is $55,229MM, a decr... | Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 158.32MM shares of AbbVie Inc (ABBV). Analyst Price Forecast Suggests 14.89% Upside As of February 9, 2023, the average one-year price target for AbbVie is $166.14. The projected annual revenue for AbbVie is $55,229MM, a decr... |
22,805 | 2023-02-09 00:00:00 UTC | US STOCKS-Wall St rises on robust earnings, Disney hits five-month high | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-st-rises-on-robust-earnings-disney-hits-five-month-high | null | null | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.
Disney jumps on Q1 beat, layoff plans
PepsiCo gains on quarterly profit, sales beat
Salesforce rises on reports Third Point owns stake
U.S. weekly jobless claims increase
Indexes up: Dow 0.71%, S&P 0.73%, Nasdaq ... | PepsiCo Inc PEP.O rose 1.6% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 4.6% after beating fourth-quarter profit expectations. Disney Co DIS.N gained 3% to its highest level since late August after topping earnings estimates and announcing 7,000 job cut... | PepsiCo Inc PEP.O rose 1.6% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 4.6% after beating fourth-quarter profit expectations. Disney jumps on Q1 beat, layoff plans PepsiCo gains on quarterly profit, sales beat Salesforce rises on reports Third Point ow... | PepsiCo Inc PEP.O rose 1.6% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 4.6% after beating fourth-quarter profit expectations. Disney jumps on Q1 beat, layoff plans PepsiCo gains on quarterly profit, sales beat Salesforce rises on reports Third Point ow... | PepsiCo Inc PEP.O rose 1.6% as the snack and beverage maker reported better-than-expected results, while drugmaker AbbVie IncABBV.N gained 4.6% after beating fourth-quarter profit expectations. Disney jumps on Q1 beat, layoff plans PepsiCo gains on quarterly profit, sales beat Salesforce rises on reports Third Point ow... |
22,806 | 2023-02-09 00:00:00 UTC | AbbVie (ABBV) Q4 Earnings Beat Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q4-earnings-beat-estimates | null | null | AbbVie (ABBV) came out with quarterly earnings of $3.60 per share, beating the Zacks Consensus Estimate of $3.54 per share. This compares to earnings of $3.31 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 1.69%. A quarter ago, it was e... | AbbVie (ABBV) came out with quarterly earnings of $3.60 per share, beating the Zacks Consensus Estimate of $3.54 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $15.12 billion for the quarter ended December 2022, missing the Zacks Consensus Estimate by 1.52%. AbbVie ... | AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $15.12 billion for the quarter ended December 2022, missing the Zacks Consensus Estimate by 1.52%. Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Sto... | AbbVie (ABBV) came out with quarterly earnings of $3.60 per share, beating the Zacks Consensus Estimate of $3.54 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $15.12 billion for the quarter ended December 2022, missing the Zacks Consensus Estimate by 1.52%. Click t... | AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $15.12 billion for the quarter ended December 2022, missing the Zacks Consensus Estimate by 1.52%. AbbVie (ABBV) came out with quarterly earnings of $3.60 per share, beating the Zacks Consensus Estimate of $3.54 per share. AbbVie ... |
22,807 | 2023-02-09 00:00:00 UTC | AbbVie's 2023 profit forecast misses as Humira faces heat from rivals | ABBV | https://www.nasdaq.com/articles/abbvies-2023-profit-forecast-misses-as-humira-faces-heat-from-rivals-0 | null | null | Adds shares
Feb 9 (Reuters) - AbbVie Inc ABBV.N on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis drug Humira faced competition from cheaper biosimilars in the United States early this year.
The company said it expected adjusted profit in the range of ... | Adds shares Feb 9 (Reuters) - AbbVie Inc ABBV.N on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis drug Humira faced competition from cheaper biosimilars in the United States early this year. AbbVie's weak forecast suggests that Humira rivals could nibb... | Adds shares Feb 9 (Reuters) - AbbVie Inc ABBV.N on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis drug Humira faced competition from cheaper biosimilars in the United States early this year. Excluding items, AbbVie earned $3.60 per share in the fourth ... | Adds shares Feb 9 (Reuters) - AbbVie Inc ABBV.N on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis drug Humira faced competition from cheaper biosimilars in the United States early this year. AbbVie's weak forecast suggests that Humira rivals could nibb... | Adds shares Feb 9 (Reuters) - AbbVie Inc ABBV.N on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis drug Humira faced competition from cheaper biosimilars in the United States early this year. AbbVie's weak forecast suggests that Humira rivals could nibb... |
22,808 | 2023-02-09 00:00:00 UTC | AbbVie Q4 22 Earnings Conference Call At 9:00 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-q4-22-earnings-conference-call-at-9%3A00-am-et | null | null | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 9, 2023, to discuss Q4 22 earnings results.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 9, 2023, to discuss Q4 22 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 9, 2023, to discuss Q4 22 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 9, 2023, to discuss Q4 22 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 9, 2023, to discuss Q4 22 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... |
22,809 | 2023-02-09 00:00:00 UTC | AbbVie Q4 Profit Decreases, but beats estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q4-profit-decreases-but-beats-estimates | null | null | (RTTNews) - AbbVie (ABBV) announced a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.
The company's earnings totaled $2.47 billion, or $1.38 per share. This compares with $4.04 billion, or $2.26 per share, in last year's fourth quarter.
Excluding items, AbbVie repo... | (RTTNews) - AbbVie (ABBV) announced a profit for fourth quarter that decreased from the same period last year but beat the Street estimates. Excluding items, AbbVie reported adjusted earnings of $6.42 billion or $3.60 per share for the period. AbbVie earnings at a glance (GAAP) : -Earnings (Q4): $2.47 Bln. | Excluding items, AbbVie reported adjusted earnings of $6.42 billion or $3.60 per share for the period. (RTTNews) - AbbVie (ABBV) announced a profit for fourth quarter that decreased from the same period last year but beat the Street estimates. AbbVie earnings at a glance (GAAP) : -Earnings (Q4): $2.47 Bln. | (RTTNews) - AbbVie (ABBV) announced a profit for fourth quarter that decreased from the same period last year but beat the Street estimates. Excluding items, AbbVie reported adjusted earnings of $6.42 billion or $3.60 per share for the period. AbbVie earnings at a glance (GAAP) : -Earnings (Q4): $2.47 Bln. | Excluding items, AbbVie reported adjusted earnings of $6.42 billion or $3.60 per share for the period. (RTTNews) - AbbVie (ABBV) announced a profit for fourth quarter that decreased from the same period last year but beat the Street estimates. AbbVie earnings at a glance (GAAP) : -Earnings (Q4): $2.47 Bln. |
22,810 | 2023-02-09 00:00:00 UTC | AbbVie's 2023 profit forecast misses as Humira faces heat from rivals | ABBV | https://www.nasdaq.com/articles/abbvies-2023-profit-forecast-misses-as-humira-faces-heat-from-rivals | null | null | Feb 9 (Reuters) - AbbVie Inc ABBV.N on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis drug Humira faced competition from cheaper biosimilars in the United States early this year.
The company said it expected adjusted profit in the range of $10.70 to $1... | Feb 9 (Reuters) - AbbVie Inc ABBV.N on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis drug Humira faced competition from cheaper biosimilars in the United States early this year. AbbVie's weak forecast suggests that Humira rivals could nibble away at t... | Feb 9 (Reuters) - AbbVie Inc ABBV.N on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis drug Humira faced competition from cheaper biosimilars in the United States early this year. Excluding items, AbbVie earned $3.60 per share in the fourth quarter, bea... | Feb 9 (Reuters) - AbbVie Inc ABBV.N on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis drug Humira faced competition from cheaper biosimilars in the United States early this year. AbbVie's weak forecast suggests that Humira rivals could nibble away at t... | AbbVie's weak forecast suggests that Humira rivals could nibble away at the blockbuster drug's market share at a faster pace this year than analysts' projections. Feb 9 (Reuters) - AbbVie Inc ABBV.N on Thursday forecast 2023 profit below Wall Street expectations, in the first outlook since its blockbuster arthritis dru... |
22,811 | 2023-02-09 00:00:00 UTC | US STOCKS-Futures rise on earnings optimism, Disney climbs on revamp plan | ABBV | https://www.nasdaq.com/articles/us-stocks-futures-rise-on-earnings-optimism-disney-climbs-on-revamp-plan | null | null | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.
Futures up: Dow 0.75%, S&P 0.90%, Nasdaq 1.30%
Feb 9 (Reuters) - U.S. stock index futures rose on Thursday as a slew of strong quarterly earnings lifted sentiment after worries that the Federal Reserve will keep ... | Tobacco firm Philip Morris International Inc PM.N, drugmaker Abbvie Inc ABBV.N, apparel maker Ralph Lauren Corp RL.N and cereal maker Kellogg Co K.N are all set to report earnings during the day. Walt Disney Co DIS.N climbed 6.6% in premarket trading after topping earnings estimates and announcing 7,000 job cuts as par... | Tobacco firm Philip Morris International Inc PM.N, drugmaker Abbvie Inc ABBV.N, apparel maker Ralph Lauren Corp RL.N and cereal maker Kellogg Co K.N are all set to report earnings during the day. Futures up: Dow 0.75%, S&P 0.90%, Nasdaq 1.30% Feb 9 (Reuters) - U.S. stock index futures rose on Thursday as a slew of stro... | Tobacco firm Philip Morris International Inc PM.N, drugmaker Abbvie Inc ABBV.N, apparel maker Ralph Lauren Corp RL.N and cereal maker Kellogg Co K.N are all set to report earnings during the day. Futures up: Dow 0.75%, S&P 0.90%, Nasdaq 1.30% Feb 9 (Reuters) - U.S. stock index futures rose on Thursday as a slew of stro... | Tobacco firm Philip Morris International Inc PM.N, drugmaker Abbvie Inc ABBV.N, apparel maker Ralph Lauren Corp RL.N and cereal maker Kellogg Co K.N are all set to report earnings during the day. PepsiCo Inc PEP.O rose 1.4% as the soda maker reported better-than-expected results for its fourth quarter. Of more than hal... |
22,812 | 2023-02-09 00:00:00 UTC | Do Humira Biosimilars Threaten AbbVie's Dividend? | ABBV | https://www.nasdaq.com/articles/do-humira-biosimilars-threaten-abbvies-dividend | null | null | Pharmaceutical giant AbbVie (NYSE: ABBV) is known for its top-selling drug Humira and its lucrative dividend that yields more than 4% at the current share price. This week Humira, which treats autoimmune diseases, is facing the first of a flood of biosimilar generics hitting the market at lower prices.
Humira is a long... | Pharmaceutical giant AbbVie (NYSE: ABBV) is known for its top-selling drug Humira and its lucrative dividend that yields more than 4% at the current share price. Answering these questions will require understanding the foundation of AbbVie's dividend payout and what other products might help make up for the potential d... | Given Humira's contribution to sales, I'll hypothetically assume that Humira contributes the same ratio to free cash flow (meaning AbbVie's margins are the same across products). ABBV cash dividend payout ratio data by YCharts. Thanks to a conservative dividend payout ratio, Skyrizi and Rinvoq, and AbbVie's strong pipe... | Humira is a big piece of the puzzle Humira's strong performance helped grow the company over the years; it made $12.5 billion in sales in 2014, approximately 62% of AbbVie's total revenue that year. Humira's 2021 sales were $20.7 billion, a more minor (but still significant) 37% of AbbVie's total sales. Given Humira's ... | AbbVie generated nearly $22 billion in free cash flow over the past year on $57.8 billion in sales, converting about 39% of its revenue to cash profits. ABBV cash dividend payout ratio data by YCharts. This could help AbbVie retain some of Humira's lost sales with new revenue from these drugs. |
22,813 | 2023-02-08 00:00:00 UTC | Vanguard Russell 1000 Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/vanguard-russell-1000-growth-etf-experiences-big-inflow | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Russell 1000 Growth ETF (Symbol: VONG) where we have detected an approximate $519.8 million dollar inflow -- that's a 5.0% increase week over week in outstanding units (from 166,631... | Among the largest underlying components of VONG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.5%, Broadcom Inc (Symbol: AVGO) is off about 0.8%, and Home Depot Inc (Symbol: HD) is lower by about 0.9%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to acco... | Among the largest underlying components of VONG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.5%, Broadcom Inc (Symbol: AVGO) is off about 0.8%, and Home Depot Inc (Symbol: HD) is lower by about 0.9%. For a complete list of holdings, visit the VONG Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of VONG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.5%, Broadcom Inc (Symbol: AVGO) is off about 0.8%, and Home Depot Inc (Symbol: HD) is lower by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... | Among the largest underlying components of VONG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.5%, Broadcom Inc (Symbol: AVGO) is off about 0.8%, and Home Depot Inc (Symbol: HD) is lower by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... |
22,814 | 2023-02-08 00:00:00 UTC | Noteworthy Wednesday Option Activity: GPRE, ABBV, K | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-gpre-abbv-k | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Green Plains Inc. (Symbol: GPRE), where a total of 4,115 contracts have traded so far, representing approximately 411,500 underlying shares. That amounts to about 48.2% of GPRE's average daily trading volume ove... | Especially high volume was seen for the $149 strike call option expiring February 24, 2023, with 1,638 contracts trading so far today, representing approximately 163,800 underlying shares of ABBV. Below is a chart showing GPRE's trailing twelve month trading history, with the $30 strike highlighted in orange: AbbVie In... | Below is a chart showing GPRE's trailing twelve month trading history, with the $30 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 29,070 contracts thus far today. That number of contracts represents approximately 2.9 million underlying shares, working out to a sizeable 47.7% of... | Especially high volume was seen for the $65 strike put option expiring February 17, 2023, with 2,966 contracts trading so far today, representing approximately 296,600 underlying shares of K. Below is a chart showing K's trailing twelve month trading history, with the $65 strike highlighted in orange: For the various d... | Especially high volume was seen for the $65 strike put option expiring February 17, 2023, with 2,966 contracts trading so far today, representing approximately 296,600 underlying shares of K. Below is a chart showing K's trailing twelve month trading history, with the $65 strike highlighted in orange: For the various d... |
22,815 | 2023-02-08 00:00:00 UTC | Pre-Market Earnings Report for February 9, 2023 : ABBV, PEP, AZN, PM, SPGI, DUK, BN, TRI, APO, HLT, TU, WTW | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-february-9-2023-%3A-abbv-pep-azn-pm-spgi-duk-bn-tri-apo-hlt-0 | null | null | The following companies are expected to report earnings prior to market open on 02/09/2023. Visit our Earnings Calendar for a full list of expected earnings releases.
AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2022. The large cap pharmaceutical company's consensus earnings per share forecast fr... | AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2022. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.47 vs. an industry ratio of 16.80. | AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2022. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.47 vs. an industry ratio of 16.80. | AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2022. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.47 vs. an industry ratio of 16.80. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2022. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.47 vs. an industry ratio of 16.80. |
22,816 | 2023-02-08 00:00:00 UTC | Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-invesco-dynamic-pharmaceuticals-etf-pjp-a-strong-etf-right-now-6 | null | null | Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Dynamic Pharmaceuticals ETF (PJP) is a smart beta exchange traded fund launched on 06/23/2005.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the market, and... | When you look at individual holdings, Pfizer Inc (PFE) accounts for about 6.84% of the fund's total assets, followed by Merck & Co Inc (MRK) and Abbvie Inc (ABBV). Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., In... | Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceut... | Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceut... | When you look at individual holdings, Pfizer Inc (PFE) accounts for about 6.84% of the fund's total assets, followed by Merck & Co Inc (MRK) and Abbvie Inc (ABBV). Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., In... |
22,817 | 2023-02-08 00:00:00 UTC | Pre-Market Earnings Report for February 9, 2023 : ABBV, PEP, AZN, PM, SPGI, DUK, BN, TRI, APO, HLT, TU, WTW | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-february-9-2023-%3A-abbv-pep-azn-pm-spgi-duk-bn-tri-apo-hlt | null | null | The following companies are expected to report earnings prior to market open on 02/09/2023. Visit our Earnings Calendar for a full list of expected earnings releases.
AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2022. The large cap pharmaceutical company's consensus earnings per share forecast fr... | AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2022. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.47 vs. an industry ratio of 16.80. | AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2022. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.47 vs. an industry ratio of 16.80. | AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2022. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.47 vs. an industry ratio of 16.80. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2022. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.47 vs. an industry ratio of 16.80. |
22,818 | 2023-02-07 00:00:00 UTC | Will AbbVie's (ABBV) New Drugs Continue to Drive Q4 Earnings? | ABBV | https://www.nasdaq.com/articles/will-abbvies-abbv-new-drugs-continue-to-drive-q4-earnings | null | null | AbbVie’s ABBV fourth-quarter revenues are likely to be driven by revenues generated from the sales of its immunology and neuroscience products.
Around half of the company’s revenues is expected to be generated from its immunology franchise, consisting of three blockbuster drugs — Humira, Rinvoq and Skyrizi. Humira, whi... | AbbVie’s ABBV fourth-quarter revenues are likely to be driven by revenues generated from the sales of its immunology and neuroscience products. Humira, which is also AbbVie’s flagship product, accounts for more than one-third of the company’s total revenues. However, AbbVie will face generic competition for Humira in t... | Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Arcus Biosciences, Inc. (RCUS) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie’s ABBV fourth-quarter ... | Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Arcus Biosciences, Inc. (RCUS) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie’s ABBV fourth-quarter ... | AbbVie’s ABBV fourth-quarter revenues are likely to be driven by revenues generated from the sales of its immunology and neuroscience products. Humira, which is also AbbVie’s flagship product, accounts for more than one-third of the company’s total revenues. However, AbbVie will face generic competition for Humira in t... |
22,819 | 2023-02-07 00:00:00 UTC | 3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-to-buy-now-for-a-lifetime-of-passive-income | null | null | Would you like a stock portfolio that generates enough passive income to fuel your retirement dreams? If you answer yes, like most investors, you owe it to yourself to check out the healthcare sector.
In the U.S. alone, healthcare-related spending reached a stunning $4.3 trillion in 2021. Unlike most areas of the econo... | AbbVie's highly profitable operation produced a whopping $21.9 billion in free cash flow over the past 12 months, and the company needed just 45% of this sum to meet its dividend commitment. AbbVie AbbVie (NYSE: ABBV) is a giant drugmaker that spun out from the healthcare conglomerate, Abbott Laboratories, in 2013. Thi... | AbbVie AbbVie (NYSE: ABBV) is a giant drugmaker that spun out from the healthcare conglomerate, Abbott Laboratories, in 2013. This is why shares of AbbVie offer a 4.1% yield that is more than twice the average yield for dividend-paying stocks in the S&P 500 index. For example, Rinvoq for arthritis and Skyrizi for psori... | This is why shares of AbbVie offer a 4.1% yield that is more than twice the average yield for dividend-paying stocks in the S&P 500 index. AbbVie AbbVie (NYSE: ABBV) is a giant drugmaker that spun out from the healthcare conglomerate, Abbott Laboratories, in 2013. For example, Rinvoq for arthritis and Skyrizi for psori... | AbbVie AbbVie (NYSE: ABBV) is a giant drugmaker that spun out from the healthcare conglomerate, Abbott Laboratories, in 2013. This is why shares of AbbVie offer a 4.1% yield that is more than twice the average yield for dividend-paying stocks in the S&P 500 index. For example, Rinvoq for arthritis and Skyrizi for psori... |
22,820 | 2023-02-06 00:00:00 UTC | US STOCKS-Wall St edges lower on Fed fears; Tyson Foods slides | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-st-edges-lower-on-fed-fears-tyson-foods-slides | null | null | By Shubham Batra and Johann M Cherian
Feb 6 (Reuters) - U.S. stock indexes edged lower on Monday with Tyson Foods falling on disappointing quarterly results, while investors reassessed their predictions on when the U.S. Federal Reserve would start cutting rates.
The report on Friday that showed the U.S. economy added j... | Traders will await earnings reports from Walt Disney Co DIS.N, PepsiCo Inc PEP.O and Abbvie Inc ABBV.N this week. By Shubham Batra and Johann M Cherian Feb 6 (Reuters) - U.S. stock indexes edged lower on Monday with Tyson Foods falling on disappointing quarterly results, while investors reassessed their predictions on ... | Traders will await earnings reports from Walt Disney Co DIS.N, PepsiCo Inc PEP.O and Abbvie Inc ABBV.N this week. By Shubham Batra and Johann M Cherian Feb 6 (Reuters) - U.S. stock indexes edged lower on Monday with Tyson Foods falling on disappointing quarterly results, while investors reassessed their predictions on ... | Traders will await earnings reports from Walt Disney Co DIS.N, PepsiCo Inc PEP.O and Abbvie Inc ABBV.N this week. By Shubham Batra and Johann M Cherian Feb 6 (Reuters) - U.S. stock indexes edged lower on Monday with Tyson Foods falling on disappointing quarterly results, while investors reassessed their predictions on ... | Traders will await earnings reports from Walt Disney Co DIS.N, PepsiCo Inc PEP.O and Abbvie Inc ABBV.N this week. By Shubham Batra and Johann M Cherian Feb 6 (Reuters) - U.S. stock indexes edged lower on Monday with Tyson Foods falling on disappointing quarterly results, while investors reassessed their predictions on ... |
22,821 | 2023-02-06 00:00:00 UTC | AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-to-report-q4-earnings%3A-whats-in-the-cards | null | null | AbbVie ABBV will report fourth-quarter and full-year 2022 results on Feb 9, before market open. In the last reported quarter, the company delivered an earnings surprise of 2.81%.
This large drugmaker’s performance has been pretty impressive, with its earnings beating estimates in each of the trailing four quarters. The... | Image Source: Zacks Investment Research Factors to Consider Strong demand for immunology and neuroscience products is expected to drive AbbVie’s fourth-quarter 2022 sales. On theearnings call investors’ focus will likely be on AbbVie’s strategies around Humira following its potential loss of exclusivity in the United S... | AbbVie markets Imbruvica in partnership with Johnson & Johnson JNJ and Venclexta in partnership with Roche RHHBY. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report AbbVie ... | Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV will report fou... | AbbVie ABBV will report fourth-quarter and full-year 2022 results on Feb 9, before market open. AbbVie Inc. Price and EPS Surprise AbbVie Inc. price-eps-surprise | AbbVie Inc. Quote AbbVie’s stock has increased 7.7% so far this year compared to the industry’s 1.9% growth. Image Source: Zacks Investment Research Factors... |
22,822 | 2023-02-06 00:00:00 UTC | 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income | ABBV | https://www.nasdaq.com/articles/3-top-ranked-dividend-stocks%3A-a-smarter-way-to-boost-your-retirement-income-52 | null | null | Believe it or not, seniors fear running out of cash more than they fear dying.
And older Americans have legitimate reasons for this worry, even if they have dutifully saved for their golden years. That's because the traditional ways people manage retirement may no longer provide enough income to meet expenses - and wit... | AbbVie (ABBV) is currently shelling out a dividend of $1.48 per share, with a dividend yield of 4.08%. Check AbbVie (ABBV) dividend history here>>> Alliance Resource Partners, L.P. (ARLP) is paying out a dividend of $0.7 per share at the moment, with a dividend yield of 8.96% compared to the Coal industry's yield of 0.... | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report Alliance Resource Partners, L.P. (ARLP) : Free Stock Analysis Report Citizens Financial Group, Inc. (CFG) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) is currently shelling out a dividend of $1.48 p... | Check AbbVie (ABBV) dividend history here>>> Alliance Resource Partners, L.P. (ARLP) is paying out a dividend of $0.7 per share at the moment, with a dividend yield of 8.96% compared to the Coal industry's yield of 0.32% and the S&P 500's yield. Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Rep... | AbbVie (ABBV) is currently shelling out a dividend of $1.48 per share, with a dividend yield of 4.08%. Check AbbVie (ABBV) dividend history here>>> Alliance Resource Partners, L.P. (ARLP) is paying out a dividend of $0.7 per share at the moment, with a dividend yield of 8.96% compared to the Coal industry's yield of 0.... |
22,823 | 2023-02-06 00:00:00 UTC | Abbvie plans to lift $2 billion cap on deals - WSJ | ABBV | https://www.nasdaq.com/articles/abbvie-plans-to-lift-%242-billion-cap-on-deals-wsj | null | null | Feb 6 (Reuters) - Abbvie ABBV.N will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billion deal for Botox maker Allergan in 2020 that shot up its debt, the company's chief executive officer told the Wall Street Journal.
Chief Executive Officer Richard Gonzalez said the company ... | Abbvie is hoping to replace the loss of revenue from Humira through its newer immunology drugs Skyrizi and Rinvoqn, and has forecast sales of over $21 billion from the two products in 2027. Feb 6 (Reuters) - Abbvie ABBV.N will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billi... | Feb 6 (Reuters) - Abbvie ABBV.N will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billion deal for Botox maker Allergan in 2020 that shot up its debt, the company's chief executive officer told the Wall Street Journal. Abbvie is hoping to replace the loss of revenue from Humir... | Feb 6 (Reuters) - Abbvie ABBV.N will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billion deal for Botox maker Allergan in 2020 that shot up its debt, the company's chief executive officer told the Wall Street Journal. Abbvie is hoping to replace the loss of revenue from Humir... | Feb 6 (Reuters) - Abbvie ABBV.N will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billion deal for Botox maker Allergan in 2020 that shot up its debt, the company's chief executive officer told the Wall Street Journal. Abbvie is hoping to replace the loss of revenue from Humir... |
22,824 | 2023-02-04 00:00:00 UTC | 2 Stocks Down More Than 6% to Buy Right Now | ABBV | https://www.nasdaq.com/articles/2-stocks-down-more-than-6-to-buy-right-now | null | null | The three major stock indexes all rose in January as many stocks soared. In fact, some of last year's biggest-losing stocks rebounded in the first month of 2023. But not every stock has taken part in this rally. In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the... | In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. Don't worry about Humira Keith Speights (AbbVie): AbbVie trounced the market last year with a 19% gain. AbbVie's top-selling drug now faces biosimila... | Don't worry about Humira Keith Speights (AbbVie): AbbVie trounced the market last year with a 19% gain. In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. AbbVie's top-selling drug now faces biosimila... | In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. AbbVie is a safe haven stock, of sorts and with the overall stock market rising, investors appear to again be shifting money to more aggressive growt... | In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. Don't worry about Humira Keith Speights (AbbVie): AbbVie trounced the market last year with a 19% gain. AbbVie's top-selling drug now faces biosimila... |
22,825 | 2023-02-04 00:00:00 UTC | 3 Unstoppable Dividend Stocks to Buy in February | ABBV | https://www.nasdaq.com/articles/3-unstoppable-dividend-stocks-to-buy-in-february | null | null | Will the stock market rise or fall in 2023? Income investors can win either way. Any time is a good time to buy solid dividend stocks.
We asked three Motley Fool contributors to identify unstoppable dividend stocks to buy in February. Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johns... | Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). Five decades of dividend increases and counting Prosper Junior Bakiny (AbbVie): In October, pharmaceutical giant AbbVie announced a 5% dividend increase that would kick in during the first quarter of this year... | Five decades of dividend increases and counting Prosper Junior Bakiny (AbbVie): In October, pharmaceutical giant AbbVie announced a 5% dividend increase that would kick in during the first quarter of this year, pushing its dividend yield to over 4%. Add another king to your hand Keith Speights (Johnson & Johnson): Like... | Five decades of dividend increases and counting Prosper Junior Bakiny (AbbVie): In October, pharmaceutical giant AbbVie announced a 5% dividend increase that would kick in during the first quarter of this year, pushing its dividend yield to over 4%. Add another king to your hand Keith Speights (Johnson & Johnson): Like... | Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). Five decades of dividend increases and counting Prosper Junior Bakiny (AbbVie): In October, pharmaceutical giant AbbVie announced a 5% dividend increase that would kick in during the first quarter of this year... |
22,826 | 2023-02-03 00:00:00 UTC | AbbVie Q4 Preview: What's in Store? | ABBV | https://www.nasdaq.com/articles/abbvie-q4-preview%3A-whats-in-store | null | null | It’s that time of the year – earnings season.
Earnings season is undoubtedly the most critical period for stocks as companies finally unveil what’s transpired behind closed doors.
So far, we’ve received a surplus of quarterly results, including those from technology titans Apple AAPL, Alphabet GOOGL, and Microsoft MSFT... | AbbVie enjoys leadership positions in key therapeutic areas, including immunology, hematologic oncology, neuroscience, aesthetics, eye care, and women’s health. Image Source: Zacks Investment Research Valuation – ABBV shares currently trade at a 12.4X forward earnings multiple, above the 9.5X five-year median by a fair... | Now, a big-time player in the Zacks Medical sector, AbbVie ABBV, is slated to unveil its quarterly results on Thursday, February 9th, before market open. Click to get this free report Apple Inc. (AAPL) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free ... | Click to get this free report Apple Inc. (AAPL) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Alphabet Inc. (GOOGL) : Fre... | Now, a big-time player in the Zacks Medical sector, AbbVie ABBV, is slated to unveil its quarterly results on Thursday, February 9th, before market open. AbbVie enjoys leadership positions in key therapeutic areas, including immunology, hematologic oncology, neuroscience, aesthetics, eye care, and women’s health. AbbVi... |
22,827 | 2023-02-03 00:00:00 UTC | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | https://www.nasdaq.com/articles/investors-heavily-search-abbvie-inc.-abbv%3A-here-is-what-you-need-to-know-3 | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this drugmaker have returned -11.4%, compared to the Zacks S&P 500 composite's +9... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals indu... | Last Reported Results and Surprise History AbbVie reported revenues of $14.81 billion in the last reported quarter, representing a year-over-year change of +3.3%. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbV... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, whi... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, whi... |
22,828 | 2023-02-03 00:00:00 UTC | 2 Steady Stocks to Buy in a Recession | ABBV | https://www.nasdaq.com/articles/2-steady-stocks-to-buy-in-a-recession | null | null | Many economic analysts continue to predict that a recession will hit the U.S. economy sometime in 2023. Equity markets already experienced a downturn last year due partly to economic troubles, so the possibility of a recession seems even more daunting than it otherwise would be. However, there are ways for investors to... | If AbbVie's predictions for these medicines are anywhere close to accurate, we can expect both to keep up their rapid sales growth for the next few years at the very least, and that's even if a recession hits. Let's look at two stocks to buy if a recession hits this year: AbbVie (NYSE: ABBV) and Incyte (NASDAQ: INCY). ... | Let's look at two stocks to buy if a recession hits this year: AbbVie (NYSE: ABBV) and Incyte (NASDAQ: INCY). AbbVie AbbVie is one of the largest pharmaceutical companies in the world. Most of AbbVie's products are must-haves -- that is, patients won't be inclined to stop buying them even in a recession. | Let's look at two stocks to buy if a recession hits this year: AbbVie (NYSE: ABBV) and Incyte (NASDAQ: INCY). AbbVie AbbVie is one of the largest pharmaceutical companies in the world. Most of AbbVie's products are must-haves -- that is, patients won't be inclined to stop buying them even in a recession. | But growth should return in 2025 as AbbVie will likely continue earning new approvals and generating profits. Let's look at two stocks to buy if a recession hits this year: AbbVie (NYSE: ABBV) and Incyte (NASDAQ: INCY). AbbVie AbbVie is one of the largest pharmaceutical companies in the world. |
22,829 | 2023-02-03 00:00:00 UTC | Is A Rise Imminent For Johnson & Johnson Stock After An 8% Fall In A Month? | ABBV | https://www.nasdaq.com/articles/is-a-rise-imminent-for-johnson-johnson-stock-after-an-8-fall-in-a-month | null | null | Johnson & Johnson stock (NYSE: JNJ) is down 8% in a month, underperforming the broader markets, with the S&P 500 index up 6%. In a recent development, a U.S. appeals court rejected J&J’s attempted use of Texas Two-Step bankruptcy strategy to offload nearly 40,000 lawsuits for its talc products. The company plans to cha... | In a recent development, a U.S. appeals court rejected J&J’s attempted use of Texas Two-Step bankruptcy strategy to offload nearly 40,000 lawsuits for its talc products. Of those 63 instances, 48 resulted in JNJ stock rising over the subsequent one-month period (twenty-one trading days). With higher inflation and the F... | Of those 63 instances, 48 resulted in JNJ stock rising over the subsequent one-month period (twenty-one trading days). Johnson & Johnson (JNJ) Return (Recent) Comparison With Peers Five-Day Return: BMY highest at 0.4%; JNJ lowest at -2.9% Ten-Day Return: BMY highest at 0.5%; JNJ lowest at -5.2% Twenty-One Day Return: B... | Johnson & Johnson stock (NYSE: JNJ) is down 8% in a month, underperforming the broader markets, with the S&P 500 index up 6%. Johnson & Johnson (JNJ) Return (Recent) Comparison With Peers Five-Day Return: BMY highest at 0.4%; JNJ lowest at -2.9% Ten-Day Return: BMY highest at 0.5%; JNJ lowest at -5.2% Twenty-One Day Re... | This historical pattern reflects 48 out of 63, or about a 76% chance of a rise in JNJ stock over the next month. This pattern suggests a higher chance of a rise in JNJ stock over the next five, ten, and twenty-one days. Johnson & Johnson (JNJ) Return (Recent) Comparison With Peers Five-Day Return: BMY highest at 0.4%; ... |
22,830 | 2023-02-02 00:00:00 UTC | ABBV March 24th Options Begin Trading | ABBV | https://www.nasdaq.com/articles/abbv-march-24th-options-begin-trading | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the March 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new March 24th contracts and identified one put and one call contract of particular interest.
The put contr... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $150.00 strike highlighted in red: Considering the fact that the $150.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $140.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $150.00 strike price has a current bid of $2.87. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new March 24th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $150.00 strike highlighted in red: Consider... |
22,831 | 2023-02-02 00:00:00 UTC | The 3 Most Undervalued Penny Stocks to Buy in February 2023 | ABBV | https://www.nasdaq.com/articles/the-3-most-undervalued-penny-stocks-to-buy-in-february-2023 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If finding undervalued stocks is good, then finding undervalued penny stocks is even better. That’s because, with penny stocks, investors’ capital appreciation upside potential is amplified.
Of course, risks are also amplified, making such companies often a... | However, the company is partnering with AbbVie (NYSE:ABBV) to bring its lead candidate, HPN217, through the clinical trial phase. Having a partner with the heft of AbbVie should do plenty to reassure investors. Canada will continue to be the world’s leading supplier, but the United States is taking steps to support its... | However, the company is partnering with AbbVie (NYSE:ABBV) to bring its lead candidate, HPN217, through the clinical trial phase. Having a partner with the heft of AbbVie should do plenty to reassure investors. InvestorPlace - Stock Market News, Stock Advice & Trading Tips If finding undervalued stocks is good, then fi... | However, the company is partnering with AbbVie (NYSE:ABBV) to bring its lead candidate, HPN217, through the clinical trial phase. Having a partner with the heft of AbbVie should do plenty to reassure investors. InvestorPlace - Stock Market News, Stock Advice & Trading Tips If finding undervalued stocks is good, then fi... | However, the company is partnering with AbbVie (NYSE:ABBV) to bring its lead candidate, HPN217, through the clinical trial phase. Having a partner with the heft of AbbVie should do plenty to reassure investors. Many of these companies are not profitable. |
22,832 | 2023-02-02 00:00:00 UTC | AbbVie (ABBV) Earnings Expected to Grow: Should You Buy? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-earnings-expected-to-grow%3A-should-you-buy | null | null | Wall Street expects a year-over-year increase in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended December 2022. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the ... | Wall Street expects a year-over-year increase in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended December 2022. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst ... | Wall Street expects a year-over-year increase in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended December 2022. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst ... | Wall Street expects a year-over-year increase in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended December 2022. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst ... | For the last reported quarter, it was expected that AbbVie would post earnings of $3.56 per share when it actually produced earnings of $3.66, delivering a surprise of +2.81%. Wall Street expects a year-over-year increase in earnings on higher revenues when AbbVie (ABBV) reports results for the quarter ended December 2... |
22,833 | 2023-02-02 00:00:00 UTC | 2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade | ABBV | https://www.nasdaq.com/articles/2-surefire-stocks-to-buy-in-2023-and-hold-for-at-least-the-next-decade | null | null | The healthcare industry has proven to be a remarkably resilient place to put capital to work in a wide range of environments. From life-saving medicines and therapies to vaccines, these are just a few examples of the essential products that healthcare companies make that render them particularly defensive investments i... | For long-term healthcare investors, AbbVie's robust portfolio of products and established track record of profitability (its annual net earnings have risen by more than 100% over the trailing five years alone) are all green flags for the company's future, even after the star power of Humira begins to recede. AbbVie Abb... | AbbVie also has top-selling products like Skyrizi, Rinvoq, Botox Therapeutic, and Botox Cosmetic in its portfolio, which helped to drive the $15 billion in net revenue and $4 billion in net income the company reported in the third quarter of 2022 alone. For long-term healthcare investors, AbbVie's robust portfolio of p... | It's also important to emphasize that while increased competition to Humira could affect AbbVie's top and bottom line as it recalibrates to other sources of growth, a number of the drug's manufacturing patents are still in force until 2034, which should continue to pose challenges to companies wishing to launch Humira ... | For long-term healthcare investors, AbbVie's robust portfolio of products and established track record of profitability (its annual net earnings have risen by more than 100% over the trailing five years alone) are all green flags for the company's future, even after the star power of Humira begins to recede. AbbVie Abb... |
22,834 | 2023-02-02 00:00:00 UTC | Merck (MRK) Beats Q4 Earnings and Revenue Estimates | ABBV | https://www.nasdaq.com/articles/merck-mrk-beats-q4-earnings-and-revenue-estimates | null | null | Merck (MRK) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.80 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 3.85%. A quarter ago, it was exp... | AbbVie (ABBV), another stock in the same industry, has yet to report results for the quarter ended December 2022. AbbVie's revenues are expected to be $15.35 billion, up 3.2% from the year-ago quarter. Click to get this free report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Ana... | Click to get this free report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV), another stock in the same industry, has yet to report results for the quarter ended December 2022. AbbVie's revenues are expecte... | AbbVie (ABBV), another stock in the same industry, has yet to report results for the quarter ended December 2022. AbbVie's revenues are expected to be $15.35 billion, up 3.2% from the year-ago quarter. Click to get this free report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Ana... | AbbVie (ABBV), another stock in the same industry, has yet to report results for the quarter ended December 2022. AbbVie's revenues are expected to be $15.35 billion, up 3.2% from the year-ago quarter. Click to get this free report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Ana... |
22,835 | 2023-02-02 00:00:00 UTC | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-proshares-sp-500-dividend-aristocrats-etf-nobl-a-strong-etf-right-now-5 | null | null | A smart beta exchange traded fund, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) debuted on 10/09/2013, and offers broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the mark... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... |
22,836 | 2023-02-01 00:00:00 UTC | FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high | ABBV | https://www.nasdaq.com/articles/focus-abbvies-humira-gets-a-u.s.-rival-but-costs-could-stay-high-1 | null | null | By Patrick Wingrove
Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.
Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... | By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... | By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. In Europe, where governments negotiate drug prices, AbbVie offered up to 80% discounts in November 2018, a... | By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... | By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. In Europe, where governments negotiate drug prices, AbbVie offered up to 80% discounts in November 2018, a... |
22,837 | 2023-02-01 00:00:00 UTC | UK pharma body urges govt to scrap hike in repayment rate for drugmakers | ABBV | https://www.nasdaq.com/articles/uk-pharma-body-urges-govt-to-scrap-hike-in-repayment-rate-for-drugmakers | null | null | Feb 2 (Reuters) - UK's pharmaceutical trade body on Thursday called for the government to scrap its plans to raise the repayment rates for drugmakers, to avoid possible setbacks in the sector.
Drugmakers that are part of UK's voluntary scheme agreement, which makes branded medicines affordable for people, are required ... | Pharmaceuticals giants AbbVie ABBV.N and Eli Lilly LLY.Nwithdrew from the UK's voluntary drug pricing agreement in January after the repayment rates surged to 26.5%. Feb 2 (Reuters) - UK's pharmaceutical trade body on Thursday called for the government to scrap its plans to raise the repayment rates for drugmakers, to ... | Pharmaceuticals giants AbbVie ABBV.N and Eli Lilly LLY.Nwithdrew from the UK's voluntary drug pricing agreement in January after the repayment rates surged to 26.5%. The Department of Health and Social Care plans to raise the revenue clawback rate to 27.5% from 24.5%. The industry body said the government policies coul... | Pharmaceuticals giants AbbVie ABBV.N and Eli Lilly LLY.Nwithdrew from the UK's voluntary drug pricing agreement in January after the repayment rates surged to 26.5%. Feb 2 (Reuters) - UK's pharmaceutical trade body on Thursday called for the government to scrap its plans to raise the repayment rates for drugmakers, to ... | Pharmaceuticals giants AbbVie ABBV.N and Eli Lilly LLY.Nwithdrew from the UK's voluntary drug pricing agreement in January after the repayment rates surged to 26.5%. Feb 2 (Reuters) - UK's pharmaceutical trade body on Thursday called for the government to scrap its plans to raise the repayment rates for drugmakers, to ... |
22,838 | 2023-02-01 00:00:00 UTC | 3 Juicy Dividend Stocks in Warren Buffett's Secret Portfolio to Buy in February | ABBV | https://www.nasdaq.com/articles/3-juicy-dividend-stocks-in-warren-buffetts-secret-portfolio-to-buy-in-february | null | null | Want to know which stocks Warren Buffett owns? First, look at Berkshire Hathaway's 13-F filings to the U.S. Securities and Exchange Commission (SEC). However, those filings won't reveal all of Buffett's stocks.
Many investors don't realize that there's another group of stocks Buffett owns in addition to the stocks list... | The company's top-selling drug, Humira, faces steep sales erosion due to biosimilar competition in the U.S. AbbVie's revenue and profits will no doubt fall significantly in 2023. AbbVie Buffett owned shares of AbbVie (NYSE: ABBV) in Berkshire's portfolio not too long ago. He subsequently exited his positions in AbbVie ... | AbbVie Buffett owned shares of AbbVie (NYSE: ABBV) in Berkshire's portfolio not too long ago. He subsequently exited his positions in AbbVie and several other big pharma stocks. However, the legendary investor nonetheless still has a stake in AbbVie through NEAM. | See the 10 stocks *Stock Advisor returns as of January 9, 2023 Keith Speights has positions in AbbVie and Berkshire Hathaway. AbbVie Buffett owned shares of AbbVie (NYSE: ABBV) in Berkshire's portfolio not too long ago. He subsequently exited his positions in AbbVie and several other big pharma stocks. | AbbVie ranks among the best dividend stocks in either of Buffett's portfolios. AbbVie Buffett owned shares of AbbVie (NYSE: ABBV) in Berkshire's portfolio not too long ago. He subsequently exited his positions in AbbVie and several other big pharma stocks. |
22,839 | 2023-02-01 00:00:00 UTC | Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints | ABBV | https://www.nasdaq.com/articles/amgen-amgn-beats-on-q4-earnings-2023-sales-view-disappoints | null | null | Amgen AMGN reported fourth-quarter 2022 earnings of $4.09 per share, which beat the Zacks Consensus Estimate of $4.04. Earnings declined 7% year over year due to a lower operating margin.
Total revenues of $6.84 billion also beat the Zacks Consensus Estimate of $6.74 billion as well as our estimate of $6.66 billion. To... | Amgevita (a biosimilar of AbbVie’s [ABBV] Humira) sales were $119 million in the quarter, up 3% year over year, driven by volume growth, which was partially offset by currency headwinds and lower net selling price due to increased competitive pressure. The same day as its earnings release, Amgen announced that it has l... | Amgevita (a biosimilar of AbbVie’s [ABBV] Humira) sales were $119 million in the quarter, up 3% year over year, driven by volume growth, which was partially offset by currency headwinds and lower net selling price due to increased competitive pressure. Click to get this free report AstraZeneca PLC (AZN) : Free Stock An... | Amgevita (a biosimilar of AbbVie’s [ABBV] Humira) sales were $119 million in the quarter, up 3% year over year, driven by volume growth, which was partially offset by currency headwinds and lower net selling price due to increased competitive pressure. The same day as its earnings release, Amgen announced that it has l... | Amgevita (a biosimilar of AbbVie’s [ABBV] Humira) sales were $119 million in the quarter, up 3% year over year, driven by volume growth, which was partially offset by currency headwinds and lower net selling price due to increased competitive pressure. The same day as its earnings release, Amgen announced that it has l... |
22,840 | 2023-01-31 00:00:00 UTC | Amgen revenue falls slightly as Lilly COVID deal contributes less | ABBV | https://www.nasdaq.com/articles/amgen-revenue-falls-slightly-as-lilly-covid-deal-contributes-less | null | null | Jan 31 (Reuters) - Amgen Inc AMGN.O on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co. LLY.N
Amgen reported revenue of $6.84 billion in the quarter, down from $6.8... | Earlier on Tuesday, Amgen launched Amjevita, the first U.S. biosimilar of AbbVie Inc's ABBV.N blockbuster arthritis treatment Humira. FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high (Reporting by Sriparna Roy in Bengaluru and Michael Erman in Maplewood, New Jersey; Editing by Bill Berkrot) ((Sriparna... | Earlier on Tuesday, Amgen launched Amjevita, the first U.S. biosimilar of AbbVie Inc's ABBV.N blockbuster arthritis treatment Humira. FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high (Reporting by Sriparna Roy in Bengaluru and Michael Erman in Maplewood, New Jersey; Editing by Bill Berkrot) ((Sriparna... | Earlier on Tuesday, Amgen launched Amjevita, the first U.S. biosimilar of AbbVie Inc's ABBV.N blockbuster arthritis treatment Humira. FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high (Reporting by Sriparna Roy in Bengaluru and Michael Erman in Maplewood, New Jersey; Editing by Bill Berkrot) ((Sriparna... | Earlier on Tuesday, Amgen launched Amjevita, the first U.S. biosimilar of AbbVie Inc's ABBV.N blockbuster arthritis treatment Humira. FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high (Reporting by Sriparna Roy in Bengaluru and Michael Erman in Maplewood, New Jersey; Editing by Bill Berkrot) ((Sriparna... |
22,841 | 2023-01-31 00:00:00 UTC | Here's What To Expect From Merck's Q4 | ABBV | https://www.nasdaq.com/articles/heres-what-to-expect-from-mercks-q4 | null | null | Merck (NYSE: MRK) is scheduled to report its Q4 2022 results on Thursday, February 2. We expect MRK stock to trade sideways, with its revenue likely falling slightly below and earnings marginally above the street estimates. Although the company should benefit from continued market share gains for Keytruda and Gardasil,... | Although the company should benefit from continued market share gains for Keytruda and Gardasil, among other products, forex headwinds may weigh on its overall performance. Looking at Q3 2022, Merck reported revenue of $15.0 billion, reflecting a significant 14% y-o-y growth, partly due to a $436 million sales contribu... | (1) Revenues expected to be slightly below the consensus estimates Trefis estimates Merck’s Q4 2022 revenues to be $13.5 billion, reflecting no growth y-o-y and slightly below the $13.7 billion consensus estimate. Looking at Q3 2022, Merck reported revenue of $15.0 billion, reflecting a significant 14% y-o-y growth, pa... | (1) Revenues expected to be slightly below the consensus estimates Trefis estimates Merck’s Q4 2022 revenues to be $13.5 billion, reflecting no growth y-o-y and slightly below the $13.7 billion consensus estimate. (3) MRK stock has little room for growth We estimate Merck’s Valuation to be $114 per share, which is only... | (1) Revenues expected to be slightly below the consensus estimates Trefis estimates Merck’s Q4 2022 revenues to be $13.5 billion, reflecting no growth y-o-y and slightly below the $13.7 billion consensus estimate. For the full year 2023, we expect the adjusted EPS to be higher at $7.58, compared to $6.02 in 2021 and an... |
22,842 | 2023-01-31 00:00:00 UTC | IWF, ABBV, HD, UNP: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/iwf-abbv-hd-unp%3A-large-outflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $1.1 billion dollar outflow -- that's a 1.8% decrease week over week (from 267,900,000 to 263,100,000). Am... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.4%, Home Depot Inc (Symbol: HD) is up about 1.7%, and Union Pacific Corp (Symbol: UNP) is higher by about 0.8%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to ... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.4%, Home Depot Inc (Symbol: HD) is up about 1.7%, and Union Pacific Corp (Symbol: UNP) is higher by about 0.8%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.4%, Home Depot Inc (Symbol: HD) is up about 1.7%, and Union Pacific Corp (Symbol: UNP) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... | Among the largest underlying components of IWF, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.4%, Home Depot Inc (Symbol: HD) is up about 1.7%, and Union Pacific Corp (Symbol: UNP) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... |
22,843 | 2023-01-31 00:00:00 UTC | FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high | ABBV | https://www.nasdaq.com/articles/focus-abbvies-humira-gets-a-u.s.-rival-but-costs-could-stay-high | null | null | By Patrick Wingrove
Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.
Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... | By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... | By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. In Europe, where governments negotiate drug prices, AbbVie offered up to 80% discounts in November 2018, a... | By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... | By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... |
22,844 | 2023-01-31 00:00:00 UTC | FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high | ABBV | https://www.nasdaq.com/articles/focus-abbvies-humira-gets-a-u.s.-rival-but-costs-could-stay-high-0 | null | null | By Patrick Wingrove
Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.
Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... | By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... | By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. In Europe, where governments negotiate drug prices, AbbVie offered up to 80% discounts in November 2018, a... | By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... | By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20... |
22,845 | 2023-01-31 00:00:00 UTC | Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates | ABBV | https://www.nasdaq.com/articles/pfizer-pfe-q4-earnings-and-revenues-beat-estimates | null | null | Pfizer (PFE) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.08 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 10.68%. A quarter ago, it was e... | Another stock from the same industry, AbbVie (ABBV), has yet to report results for the quarter ended December 2022. AbbVie's revenues are expected to be $15.35 billion, up 3.2% from the year-ago quarter. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysi... | Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, AbbVie (ABBV), has yet to report results for the quarter ended December 2022. AbbVie's revenues are expected to... | Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, AbbVie (ABBV), has yet to report results for the quarter ended December 2022. AbbVie's revenues are expected to... | Another stock from the same industry, AbbVie (ABBV), has yet to report results for the quarter ended December 2022. AbbVie's revenues are expected to be $15.35 billion, up 3.2% from the year-ago quarter. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysi... |
22,846 | 2023-01-30 00:00:00 UTC | AbbVie (ABBV) Stock Moves -0.43%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-0.43%3A-what-you-should-know | null | null | AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day. This move was narrower than the S&P 500's daily loss of 1.3%. Elsewhere, the Dow lost 0.77%, while the tech-heavy Nasdaq lost 5.51%.
Heading into today, shares of the drugmaker had lost 9.49% over the past month, la... | AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.59 per share, which would represent year-over-year gro... | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings r... | AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.59 per share, which would represent year-over-year gro... | AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.59 per share, which would represent year-over-year gro... |
22,847 | 2023-01-30 00:00:00 UTC | Dividends for Stability, Safety in a Mixed Market | ABBV | https://www.nasdaq.com/articles/dividends-for-stability-safety-in-a-mixed-market | null | null | A
few weeks ago, we talked to you about the 2023 stock market outlooks from a number of Wall Street strategists. By and large, those experts were more optimistic about this year than last, but many believe we'll still have to ensure more turbulence before reaching clearer skies.
This week, we'll discuss one way to navi... | AbbVie (ABBV, 4.0% yield): "AbbVie is unique because they have the largest/most successful drug ever produced in Humira, which is losing exclusivity in the U.S. over the next few years. Some say with Humira going away, AbbVie is worthless. But AbbVie has new drugs [Rinvoq and Skyrizi] that are taking over the Humira bu... | AbbVie (ABBV, 4.0% yield): "AbbVie is unique because they have the largest/most successful drug ever produced in Humira, which is losing exclusivity in the U.S. over the next few years. Some say with Humira going away, AbbVie is worthless. But AbbVie has new drugs [Rinvoq and Skyrizi] that are taking over the Humira bu... | AbbVie (ABBV, 4.0% yield): "AbbVie is unique because they have the largest/most successful drug ever produced in Humira, which is losing exclusivity in the U.S. over the next few years. Some say with Humira going away, AbbVie is worthless. But AbbVie has new drugs [Rinvoq and Skyrizi] that are taking over the Humira bu... | AbbVie (ABBV, 4.0% yield): "AbbVie is unique because they have the largest/most successful drug ever produced in Humira, which is losing exclusivity in the U.S. over the next few years. Some say with Humira going away, AbbVie is worthless. But AbbVie has new drugs [Rinvoq and Skyrizi] that are taking over the Humira bu... |
22,848 | 2023-01-30 00:00:00 UTC | How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks | ABBV | https://www.nasdaq.com/articles/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks-43 | null | null | Here's an eye-opening statistic: older Americans are more afraid of running out of money than of death itself.
And unfortunately, even retirees who have built a nest egg have good reason to be concerned - with the traditional approaches to retirement planning, income may no longer cover expenses. That means retirees ar... | AbbVie (ABBV) is currently shelling out a dividend of $1.48 per share, with a dividend yield of 4.05%. Check AbbVie (ABBV) dividend history here>>> Conagra Brands (CAG) is paying out a dividend of $0.33 per share at the moment, with a dividend yield of 3.62% compared to the Food - Miscellaneous industry's yield of 0% a... | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report Conagra Brands (CAG) : Free Stock Analysis Report MidWestOne Financial Group, Inc. (MOFG) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) is currently shelling out a dividend of $1.48 per share, with a... | Check AbbVie (ABBV) dividend history here>>> Conagra Brands (CAG) is paying out a dividend of $0.33 per share at the moment, with a dividend yield of 3.62% compared to the Food - Miscellaneous industry's yield of 0% and the S&P 500's yield. AbbVie (ABBV) is currently shelling out a dividend of $1.48 per share, with a d... | Check AbbVie (ABBV) dividend history here>>> Conagra Brands (CAG) is paying out a dividend of $0.33 per share at the moment, with a dividend yield of 3.62% compared to the Food - Miscellaneous industry's yield of 0% and the S&P 500's yield. AbbVie (ABBV) is currently shelling out a dividend of $1.48 per share, with a d... |
22,849 | 2023-01-30 00:00:00 UTC | Why AbbVie is a Top Socially Responsible Dividend Stock (ABBV) | ABBV | https://www.nasdaq.com/articles/why-abbvie-is-a-top-socially-responsible-dividend-stock-abbv | null | null | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | Below is a long-term dividend history chart for ABBV, which the DividendRank report stressed as being of key importance. AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.0% yield... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.0% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... |
22,850 | 2023-01-30 00:00:00 UTC | Down 14.5%, Is Pfizer Stock a Screaming Buy? | ABBV | https://www.nasdaq.com/articles/down-14.5-is-pfizer-stock-a-screaming-buy | null | null | As the major U.S. stock indices fell into bear territory in 2022, big pharma stocks quickly became an oasis for nervous investors -- in many cases thanks to their largely recession-proof business models, reliable cash flows, and dependable quarterly dividends.
AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Eli ... | AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), and Merck (NYSE: MRK) all trounced the broader markets last year: LLY Total Return Level data by YCharts. Despite executing multiple recent deals for high-value medications like the migraine drug Nurtec, the sickle cell disease therapy Oxbryt... | AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), and Merck (NYSE: MRK) all trounced the broader markets last year: LLY Total Return Level data by YCharts. Pfizer's valuation, dividend, and development capacity are buy signals Pfizer's breathtaking nosedive over the prior 13 months isn't all... | AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), and Merck (NYSE: MRK) all trounced the broader markets last year: LLY Total Return Level data by YCharts. Pfizer's valuation, dividend, and development capacity are buy signals Pfizer's breathtaking nosedive over the prior 13 months isn't all... | AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), and Merck (NYSE: MRK) all trounced the broader markets last year: LLY Total Return Level data by YCharts. The anticipated decline in COVID-19 product sales this year, and a series of expiring patents for drugs like Eliquis, Ibrance, and Xelja... |
22,851 | 2023-01-30 00:00:00 UTC | Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod | ABBV | https://www.nasdaq.com/articles/eli-lilly-lly-lymphoma-candidate-pirtobrutinib-gets-fda-nod | null | null | Eli Lilly and Company LLY announced that the FDA, under an accelerated approval pathway, approved BTK inhibitor, pirtobrutinib (100 mg & 50 mg tablets) for the treatment of relapsed or refractory mantle cell lymphoma (MCL), in adult patients. The drug will be marketed by the trade name of Jaypirca and can be administer... | However, Lilly’s Jaypirca is subject to stiff competition from AbbVie’s ABBV Imbruvica, which is approved for hematological cancers in five distinct disease areas. In the third quarter of 2023, AbbVie’s U.S. sales of Imbruvica grossed $849 million, down 23.5% from the year-ago figure. AbbVie’s share of profit from the ... | Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. However, Lilly’s Jaypirca is subject to stiff... | Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. However, Lilly’s Jaypirca is subject to stiff... | However, Lilly’s Jaypirca is subject to stiff competition from AbbVie’s ABBV Imbruvica, which is approved for hematological cancers in five distinct disease areas. In the third quarter of 2023, AbbVie’s U.S. sales of Imbruvica grossed $849 million, down 23.5% from the year-ago figure. AbbVie’s share of profit from the ... |
22,852 | 2023-01-28 00:00:00 UTC | 7 Dividend Stocks to Buy Now or You’ll Be Kicking Yourself Later | ABBV | https://www.nasdaq.com/articles/7-dividend-stocks-to-buy-now-or-youll-be-kicking-yourself-later | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The recent rally in equities may be prying some cash off the sidelines. But if you’re investing in pure growth stocks and avoiding dividend stocks altogether, I’d urge caution.
No, I’m not talking about what the Federal Reserve will do with interest rates. ... | CVX Chevron $179.45 VZ Verizon $40.64 KO Coca-Cola $60.49 PEP PepsiCo $169.62 ABBV AbbVie $146.28 LOW Lowe’s $202.49 UNH UnitedHealth Group $486.05 Chevron (CVX) Source: tishomir / Shutterstock.com Chevron (NYSE:CVX) is one of the first dividend stocks that came to mind, mainly because the company recently announced a ... | CVX Chevron $179.45 VZ Verizon $40.64 KO Coca-Cola $60.49 PEP PepsiCo $169.62 ABBV AbbVie $146.28 LOW Lowe’s $202.49 UNH UnitedHealth Group $486.05 Chevron (CVX) Source: tishomir / Shutterstock.com Chevron (NYSE:CVX) is one of the first dividend stocks that came to mind, mainly because the company recently announced a ... | CVX Chevron $179.45 VZ Verizon $40.64 KO Coca-Cola $60.49 PEP PepsiCo $169.62 ABBV AbbVie $146.28 LOW Lowe’s $202.49 UNH UnitedHealth Group $486.05 Chevron (CVX) Source: tishomir / Shutterstock.com Chevron (NYSE:CVX) is one of the first dividend stocks that came to mind, mainly because the company recently announced a ... | CVX Chevron $179.45 VZ Verizon $40.64 KO Coca-Cola $60.49 PEP PepsiCo $169.62 ABBV AbbVie $146.28 LOW Lowe’s $202.49 UNH UnitedHealth Group $486.05 Chevron (CVX) Source: tishomir / Shutterstock.com Chevron (NYSE:CVX) is one of the first dividend stocks that came to mind, mainly because the company recently announced a ... |
22,853 | 2023-01-28 00:00:00 UTC | 2 of the Best Dividend Stocks to Own in 2023 | ABBV | https://www.nasdaq.com/articles/2-of-the-best-dividend-stocks-to-own-in-2023 | null | null | Investors don't yet know what to expect in 2023. The market may slowly stroll along the path to recovery. Or it could race ahead, with stock prices soaring. In either case, it's a good idea to add some dividend stocks to your portfolio. They'll offer you guaranteed income no matter what the market does.
But which playe... | AbbVie's biggest blockbuster, immunology drug Humira, is set to face competition. AbbVie AbbVie (NYSE: ABBV) pays investors an annual dividend of $5.92, representing a yield of 4.02%. ABBV Free Cash Flow data by YCharts You can count on AbbVie for solid passive income and growth of that income over time. | AbbVie AbbVie (NYSE: ABBV) pays investors an annual dividend of $5.92, representing a yield of 4.02%. ABBV Free Cash Flow data by YCharts You can count on AbbVie for solid passive income and growth of that income over time. Like J&J, AbbVie's 2023 will be one of transition. | AbbVie AbbVie (NYSE: ABBV) pays investors an annual dividend of $5.92, representing a yield of 4.02%. ABBV Free Cash Flow data by YCharts You can count on AbbVie for solid passive income and growth of that income over time. Like J&J, AbbVie's 2023 will be one of transition. | AbbVie AbbVie (NYSE: ABBV) pays investors an annual dividend of $5.92, representing a yield of 4.02%. ABBV Free Cash Flow data by YCharts You can count on AbbVie for solid passive income and growth of that income over time. Like J&J, AbbVie's 2023 will be one of transition. |
22,854 | 2023-01-26 00:00:00 UTC | Interesting ABBV Put And Call Options For March 10th | ABBV | https://www.nasdaq.com/articles/interesting-abbv-put-and-call-options-for-march-10th | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the March 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new March 10th contracts and identified one put and one call contract of particular interest.
The put contract... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $150.00 strike highlighted in red: Considering the fact that the $150.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $145.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $150.00 strike price has a current bid of $3.80. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new March 10th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $150.00 strike highlighted in red: Consider... |
22,855 | 2023-01-25 00:00:00 UTC | Want Safety and Growth in 2023? Try These Dividend Stocks. | ABBV | https://www.nasdaq.com/articles/want-safety-and-growth-in-2023-try-these-dividend-stocks. | null | null | Last year was a tough one for most companies and investors. The three major indexes touched bear territory. And even the strongest of companies saw their share prices slip. Everyone is hoping 2023 will bring better days. History indicates this might happen. Still, to maximize your chances of winning this year and over ... | ABBV Free Cash Flow data by YCharts This combination of blockbuster products that patients need and a dividend you can count on make AbbVie a stock to buy -- no matter what the market does this year. AbbVie AbbVie (NYSE: ABBV) makes the world's best-selling drug. But here's why AbbVie is about to embark on a whole new ... | And AbbVie's rising free cash flow indicates it has what it takes to keep increasing its dividend. ABBV Free Cash Flow data by YCharts This combination of blockbuster products that patients need and a dividend you can count on make AbbVie a stock to buy -- no matter what the market does this year. AbbVie AbbVie (NYSE: ... | ABBV Free Cash Flow data by YCharts This combination of blockbuster products that patients need and a dividend you can count on make AbbVie a stock to buy -- no matter what the market does this year. AbbVie AbbVie (NYSE: ABBV) makes the world's best-selling drug. But here's why AbbVie is about to embark on a whole new ... | AbbVie AbbVie (NYSE: ABBV) makes the world's best-selling drug. But here's why AbbVie is about to embark on a whole new phase of growth. AbbVie expects peak sales of Rinvoq and Skyrizi to beat those of Humira by 2027. |
22,856 | 2023-01-25 00:00:00 UTC | Is the Pain Over for Baudax Bio Investors after a 70% Spike? | ABBV | https://www.nasdaq.com/articles/is-the-pain-over-for-baudax-bio-investors-after-a-70-spike | null | null | Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. While the interim positive outcome is based on a 20-patient group, it expects to complete the phase 2 trial with 80 patients by the end of the first quarter of 2023.
The d... | Some of the larger pharmaceutical companies that make NMBA include AbbVie Inc. (NYSE: ABBV), Pfizer (NYSE: PFE), Allergan PLC (NYSE: AGN), and Merck & Co. Inc (NYSE: MRK). Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.... | Some of the larger pharmaceutical companies that make NMBA include AbbVie Inc. (NYSE: ABBV), Pfizer (NYSE: PFE), Allergan PLC (NYSE: AGN), and Merck & Co. Inc (NYSE: MRK). Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.... | Some of the larger pharmaceutical companies that make NMBA include AbbVie Inc. (NYSE: ABBV), Pfizer (NYSE: PFE), Allergan PLC (NYSE: AGN), and Merck & Co. Inc (NYSE: MRK). Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.... | Some of the larger pharmaceutical companies that make NMBA include AbbVie Inc. (NYSE: ABBV), Pfizer (NYSE: PFE), Allergan PLC (NYSE: AGN), and Merck & Co. Inc (NYSE: MRK). Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.... |
22,857 | 2023-01-25 00:00:00 UTC | 3 Reasons to Buy AbbVie and 2 Reasons Not to Buy | ABBV | https://www.nasdaq.com/articles/3-reasons-to-buy-abbvie-and-2-reasons-not-to-buy | null | null | 2023 is expected to be an important year for AbbVie (NYSE: ABBV). The pharmaceutical company is facing its first biosimilar competition in the United States. It's big news because it involves AbbVie's monoclonal antibody blockbuster therapy, Humira, which is on track to generate a second consecutive year of $20 billion... | It's big news because it involves AbbVie's monoclonal antibody blockbuster therapy, Humira, which is on track to generate a second consecutive year of $20 billion-plus in revenue in 2022. 2023 is expected to be an important year for AbbVie (NYSE: ABBV). As they process what to do about the stock, here are three reasons... | Reason to buy: You can't ignore AbbVie's growing portfolio and pipeline Humira already has two immunology drugs, Skyrizi and Rinvoq, that it expects to replace Humira's lost revenue. Reason to buy: AbbVie's dividend is too good to ignore AbbVie raised its quarterly dividend by 5% this year to $1.48 per share, the 51st ... | Reason to buy: Declining Humira sales have already been priced into the stock Through the first nine months of 2022, AbbVie reported revenue of $42.9 billion, up 3.9% year over year. Reason to buy: AbbVie's dividend is too good to ignore AbbVie raised its quarterly dividend by 5% this year to $1.48 per share, the 51st ... | Reason to buy: Declining Humira sales have already been priced into the stock Through the first nine months of 2022, AbbVie reported revenue of $42.9 billion, up 3.9% year over year. Reason to buy: You can't ignore AbbVie's growing portfolio and pipeline Humira already has two immunology drugs, Skyrizi and Rinvoq, that... |
22,858 | 2023-01-24 00:00:00 UTC | Sum Up The Parts: USMV Could Be Worth $80 | ABBV | https://www.nasdaq.com/articles/sum-up-the-parts%3A-usmv-could-be-worth-%2480 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Min Vol Factor... | iShares MSCI USA Min Vol Factor ETF USMV $72.67 $79.77 9.77% Home Depot Inc HD $315.48 $350.29 11.03% AbbVie Inc ABBV $148.55 $164.71 10.88% PepsiCo Inc PEP $169.12 $187.00 10.57% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of USMV's u... | Three of USMV's underlying holdings with notable upside to their analyst target prices are Home Depot Inc (Symbol: HD), AbbVie Inc (Symbol: ABBV), and PepsiCo Inc (Symbol: PEP). iShares MSCI USA Min Vol Factor ETF USMV $72.67 $79.77 9.77% Home Depot Inc HD $315.48 $350.29 11.03% AbbVie Inc ABBV $148.55 $164.71 10.88% P... | Similarly, ABBV has 10.88% upside from the recent share price of $148.55 if the average analyst target price of $164.71/share is reached, and analysts on average are expecting PEP to reach a target price of $187.00/share, which is 10.57% above the recent price of $169.12. Three of USMV's underlying holdings with notabl... | iShares MSCI USA Min Vol Factor ETF USMV $72.67 $79.77 9.77% Home Depot Inc HD $315.48 $350.29 11.03% AbbVie Inc ABBV $148.55 $164.71 10.88% PepsiCo Inc PEP $169.12 $187.00 10.57% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of USMV's u... |
22,859 | 2023-01-23 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-7 | null | null | AbbVie (ABBV) closed the most recent trading day at $148.55, moving -0.7% from the previous trading session. This change lagged the S&P 500's daily gain of 1.19%. At the same time, the Dow added 0.76%, and the tech-heavy Nasdaq gained 0.29%.
Heading into today, shares of the drugmaker had lost 8.28% over the past month... | AbbVie (ABBV) closed the most recent trading day at $148.55, moving -0.7% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be February 9, 2023. In that report, analysts expect AbbVie to post earnings of $3.65 per share. | AbbVie (ABBV) closed the most recent trading day at $148.55, moving -0.7% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be February 9, 2023. In that report, analysts expect AbbVie to post earnings of $3.65 per share. | AbbVie (ABBV) closed the most recent trading day at $148.55, moving -0.7% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be February 9, 2023. In that report, analysts expect AbbVie to post earnings of $3.65 per share. | AbbVie (ABBV) closed the most recent trading day at $148.55, moving -0.7% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be February 9, 2023. In that report, analysts expect AbbVie to post earnings of $3.65 per share. |
22,860 | 2023-01-23 00:00:00 UTC | AbbVie Enters Oversold Territory | ABBV | https://www.nasdaq.com/articles/abbvie-enters-oversold-territory-0 | null | null | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. AbbVie Inc (Symbol: ABBV) presently has an... | A bullish investor could look at ABBV's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. AbbVie Inc (Symbol: ABBV) presently has an excellent rank, in the top 25% of the coverage universe, which sugges... | In the case of AbbVie Inc, the RSI reading has hit 29.0 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 55.5. Indeed, ABBV's recent annualized dividend of 5.92/share (currently paid in quarterly installments) works out to an annual yield of 3.96% based upon t... | In the case of AbbVie Inc, the RSI reading has hit 29.0 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 55.5. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABBV is its dividend history. AbbVie Inc (Sym... | Indeed, ABBV's recent annualized dividend of 5.92/share (currently paid in quarterly installments) works out to an annual yield of 3.96% based upon the recent $149.59 share price. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABBV is its dividend history. AbbVie... |
22,861 | 2023-01-23 00:00:00 UTC | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-attracting-investor-attention%3A-here-is-what-you-should-know-4 | null | null | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this drugmaker have returned -8.3%, compared to the Zacks S&P 500 composite's +4.1% change. Dur... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry... | Last Reported Results and Surprise History AbbVie reported revenues of $14.81 billion in the last reported quarter, representing a year-over-year change of +3.3%. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie ... | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has lost 2%. For the current quarter, AbbVie is expected to post earnings of $3.65 per share, indicating a change of +10.3% from the year-ago quarter. | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has lost 2%. For the current quarter, AbbVie is expected to post earnings of $3.65 per share, indicating a change of +10.3% from the year-ago quarter. |
22,862 | 2023-01-22 00:00:00 UTC | AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry. | ABBV | https://www.nasdaq.com/articles/abbvie-is-set-to-lose-on-its-biggest-blockbuster.-heres-why-you-shouldnt-worry. | null | null | AbbVie (NYSE: ABBV) boasts a portfolio of drugs across immunology, neuroscience, aesthetics, oncology, and eye care. Yet investors' focus lately has been on the fate of one particular product: the immunology drug Humira. That's because it's set to face competition in the U.S. as of this month.
Why is this such a proble... | AbbVie (NYSE: ABBV) boasts a portfolio of drugs across immunology, neuroscience, aesthetics, oncology, and eye care. The question is this: Should you buy AbbVie stock now, or wait until the newer immunology drugs truly start compensating for the Humira loss? AbbVie, of course, has seen this day coming for a long while,... | AbbVie (NYSE: ABBV) boasts a portfolio of drugs across immunology, neuroscience, aesthetics, oncology, and eye care. AbbVie, of course, has seen this day coming for a long while, and the pharmaceutical giant has been taking action. AbbVie continues to study Rinvoq in five additional indications. | The question is this: Should you buy AbbVie stock now, or wait until the newer immunology drugs truly start compensating for the Humira loss? First, though Humira is a big product, it's not AbbVie's only drug. AbbVie (NYSE: ABBV) boasts a portfolio of drugs across immunology, neuroscience, aesthetics, oncology, and eye... | First, though Humira is a big product, it's not AbbVie's only drug. AbbVie (NYSE: ABBV) boasts a portfolio of drugs across immunology, neuroscience, aesthetics, oncology, and eye care. AbbVie, of course, has seen this day coming for a long while, and the pharmaceutical giant has been taking action. |
22,863 | 2023-01-20 00:00:00 UTC | Noteworthy Friday Option Activity: IBM, ATVI, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-ibm-atvi-abbv | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in International Business Machines Corp (Symbol: IBM), where a total volume of 89,115 contracts has been traded thus far today, a contract volume which is representative of approximately 8.9 million underlying ... | Especially high volume was seen for the $135 strike put option expiring February 17, 2023, with 12,024 contracts trading so far today, representing approximately 1.2 million underlying shares of ABBV. Below is a chart showing ATVI's trailing twelve month trading history, with the $80 strike highlighted in orange: And A... | That number of contracts represents approximately 5.2 million underlying shares, working out to a sizeable 103.2% of ABBV's average daily trading volume over the past month, of 5.1 million shares. Below is a chart showing ATVI's trailing twelve month trading history, with the $80 strike highlighted in orange: And AbbVi... | That number of contracts represents approximately 5.2 million underlying shares, working out to a sizeable 103.2% of ABBV's average daily trading volume over the past month, of 5.1 million shares. Below is a chart showing ATVI's trailing twelve month trading history, with the $80 strike highlighted in orange: And AbbVi... | That number of contracts represents approximately 5.2 million underlying shares, working out to a sizeable 103.2% of ABBV's average daily trading volume over the past month, of 5.1 million shares. Especially high volume was seen for the $135 strike put option expiring February 17, 2023, with 12,024 contracts trading so... |
22,864 | 2023-01-19 00:00:00 UTC | ABBV Crosses Above 4% Yield Territory | ABBV | https://www.nasdaq.com/articles/abbv-crosses-above-4-yield-territory | null | null | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.33 on the day. Dividends are particularly important for investor... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.33 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.33 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.33 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 4% mark based on its quarterly dividend (annualized to $5.92), with the stock changing hands as low as $147.33 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, ... |
22,865 | 2023-01-19 00:00:00 UTC | 3 Unstoppable Stocks to Keep Buying in 2023 | ABBV | https://www.nasdaq.com/articles/3-unstoppable-stocks-to-keep-buying-in-2023 | null | null | Last year's market wasn't gloomy for every company. Investors bought certain stocks hand over fist. In most cases, these particular companies offered investors a solid reason to be optimistic about their future. And that's why they were able to defy the bear market.
I can easily think of three examples in the healthcar... | And AbbVie (NYSE: ABBV) -- facing declines in its biggest drug -- offered hope newer products would generate even more growth over time. AbbVie AbbVie is another stock that's worried investors. But here's why investors felt optimistic about AbbVie last year -- and should feel that way today, too. | And AbbVie (NYSE: ABBV) -- facing declines in its biggest drug -- offered hope newer products would generate even more growth over time. AbbVie AbbVie is another stock that's worried investors. But here's why investors felt optimistic about AbbVie last year -- and should feel that way today, too. | And AbbVie (NYSE: ABBV) -- facing declines in its biggest drug -- offered hope newer products would generate even more growth over time. AbbVie AbbVie is another stock that's worried investors. But here's why investors felt optimistic about AbbVie last year -- and should feel that way today, too. | And AbbVie (NYSE: ABBV) -- facing declines in its biggest drug -- offered hope newer products would generate even more growth over time. AbbVie AbbVie is another stock that's worried investors. But here's why investors felt optimistic about AbbVie last year -- and should feel that way today, too. |
22,866 | 2023-01-18 00:00:00 UTC | AbbVie Breaks Below 200-Day Moving Average - Notable for ABBV | ABBV | https://www.nasdaq.com/articles/abbvie-breaks-below-200-day-moving-average-notable-for-abbv | null | null | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $150.37, changing hands as low as $149.09 per share. AbbVie Inc shares are currently trading off about 2.4% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving aver... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $150.37, changing hands as low as $149.09 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week ra... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $150.37, changing hands as low as $149.09 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week ra... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $150.37, changing hands as low as $149.09 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week ra... | In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $150.37, changing hands as low as $149.09 per share. AbbVie Inc shares are currently trading off about 2.4% on the day. The ABBV DMA information above was sourced from TechnicalAnalysisChannel.com Click here to fi... |
22,867 | 2023-01-18 00:00:00 UTC | 7 Biotech Stocks That Will Make You Rich in 10 Years | ABBV | https://www.nasdaq.com/articles/7-biotech-stocks-that-will-make-you-rich-in-10-years | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they’re seemingly one news item away from disaster. Further, th... | ABBV AbbVie $149.57 PFE Pfizer $45.08 INCY Incyte $82.14 EXEL Exelixis $16.40 CRSP CRISPR Therapeutics $51.00 SRPT Sarepta $128.73 CVAC CureVac $9.50 AbbVie (ABBV) Source: shutterstock.com/Romix Image One of the giants in the pharmaceutical space is AbbVie (NYSE:ABBV). Through the takeover, AbbVie now commands the wrin... | ABBV AbbVie $149.57 PFE Pfizer $45.08 INCY Incyte $82.14 EXEL Exelixis $16.40 CRSP CRISPR Therapeutics $51.00 SRPT Sarepta $128.73 CVAC CureVac $9.50 AbbVie (ABBV) Source: shutterstock.com/Romix Image One of the giants in the pharmaceutical space is AbbVie (NYSE:ABBV). Through the takeover, AbbVie now commands the wrin... | ABBV AbbVie $149.57 PFE Pfizer $45.08 INCY Incyte $82.14 EXEL Exelixis $16.40 CRSP CRISPR Therapeutics $51.00 SRPT Sarepta $128.73 CVAC CureVac $9.50 AbbVie (ABBV) Source: shutterstock.com/Romix Image One of the giants in the pharmaceutical space is AbbVie (NYSE:ABBV). Through the takeover, AbbVie now commands the wrin... | ABBV AbbVie $149.57 PFE Pfizer $45.08 INCY Incyte $82.14 EXEL Exelixis $16.40 CRSP CRISPR Therapeutics $51.00 SRPT Sarepta $128.73 CVAC CureVac $9.50 AbbVie (ABBV) Source: shutterstock.com/Romix Image One of the giants in the pharmaceutical space is AbbVie (NYSE:ABBV). Through the takeover, AbbVie now commands the wrin... |
22,868 | 2023-01-18 00:00:00 UTC | 2 Cheap Growth Stocks That Can Set You Up for Life | ABBV | https://www.nasdaq.com/articles/2-cheap-growth-stocks-that-can-set-you-up-for-life | null | null | Many would-be growth stocks out there are trading at valuations that aren't nearly as high as they were just a year or two ago. That suggests there are some deals out there for investors who know what to look for. Even if growth stocks don't fully recover this year, buying shares of growing businesses and holding them ... | A couple of stocks that should be on your radar right now are AbbVie (NYSE: ABBV) and Microsoft (NASDAQ: MSFT). AbbVie AbbVie is an underrated healthcare stock that's trading at just 20 times its earnings. AbbVie even recently upgraded the guidance for the two immunology drugs in question -- Skyrizi and Rinvoq. | That growth the business will generate in the future will go great with the attractive dividend yield of 3.9% that AbbVie offers, which is well above the S&P 500 average of 1.7%. With a manageable payout ratio of 74% and more growth in its future, AbbVie makes for a solid income-generating investment. A couple of stock... | A couple of stocks that should be on your radar right now are AbbVie (NYSE: ABBV) and Microsoft (NASDAQ: MSFT). AbbVie AbbVie is an underrated healthcare stock that's trading at just 20 times its earnings. AbbVie even recently upgraded the guidance for the two immunology drugs in question -- Skyrizi and Rinvoq. | AbbVie AbbVie is an underrated healthcare stock that's trading at just 20 times its earnings. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! A couple of stocks that should be on your radar right now are AbbVie (NYSE: ABBV) and Microsoft (N... |
22,869 | 2023-01-18 00:00:00 UTC | Pick Either Johnson & Johnson Stock Or Its Peer – Both May Offer Similar Returns | ABBV | https://www.nasdaq.com/articles/pick-either-johnson-johnson-stock-or-its-peer-both-may-offer-similar-returns | null | null | We believe that pharmaceutical giants Johnson & Johnson stock (NYSE: JNJ) and Merck stock (NYSE: MRK) will likely offer similar returns over the next three years. Both companies are trading at a similar valuation of around 5.0x trailing revenues. If we look at stock returns, Merck, with a stellar 37% rise in the last ... | If we look at stock returns, Merck, with a stellar 37% rise in the last twelve months, has fared far better than J&J, up just 3%, and both have outperformed the broader S&P 500 index, down 15%. Merck, over the recent years, has benefited from the label expansion of Keytruda and strong demand for vaccines, primarily Gar... | We believe that pharmaceutical giants Johnson & Johnson stock (NYSE: JNJ) and Merck stock (NYSE: MRK) will likely offer similar returns over the next three years. Our Johnson & Johnson Operating Income Comparison and Merck Operating Income Comparison dashboards have more details. The table below summarizes our revenue... | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Johnson & Johnson vs. Merck: Which Stock Is A Better Bet? Our Johnson & Johnson Revenue Comparison and Merck Revenue Comparison dashboards provide more insight into the companies’ sales. The ... | Both companies are trading at a similar valuation of around 5.0x trailing revenues. For companies registering positive revenue growth during Covid, we consider yearly average growth before Covid with a certain weight to growth during Covid and the last twelve months. The table below summarizes our revenue and return ex... |
22,870 | 2023-01-17 00:00:00 UTC | With Competition on the Rise, Is AbbVie's Dividend Safe? | ABBV | https://www.nasdaq.com/articles/with-competition-on-the-rise-is-abbvies-dividend-safe | null | null | The moment AbbVie's (NYSE: ABBV) shareholders have been dreading for years is finally coming. In late January, the company will start facing generic competition in the U.S. for its best-selling product, immunology drug Humira. Humira has been AbbVie's key asset since it became a stand-alone company in 2013.
The pharma ... | ABBV Total Return Level data by YCharts Management doesn't seem too worried In October 2022, AbbVie announced a 5% dividend increase -- starting with the one that will be payable in February -- when it released its third-quarter earnings report. The moment AbbVie's (NYSE: ABBV) shareholders have been dreading for years... | And beyond its reasonable cash payout ratio, AbbVie and its shareholders have other reasons not to be worried. The moment AbbVie's (NYSE: ABBV) shareholders have been dreading for years is finally coming. Humira has been AbbVie's key asset since it became a stand-alone company in 2013. | ABBV Total Return Level data by YCharts Management doesn't seem too worried In October 2022, AbbVie announced a 5% dividend increase -- starting with the one that will be payable in February -- when it released its third-quarter earnings report. So even a non-negligible decrease in AbbVie's cash flow generation that le... | What's more, AbbVie's new growth drivers should exceed Humira's peak annual sales by 2027, generating more than $21 billion in revenue by then. The moment AbbVie's (NYSE: ABBV) shareholders have been dreading for years is finally coming. Humira has been AbbVie's key asset since it became a stand-alone company in 2013. |
22,871 | 2023-01-17 00:00:00 UTC | Could This FDA Approval Boost AbbVie's Stock? | ABBV | https://www.nasdaq.com/articles/could-this-fda-approval-boost-abbvies-stock | null | null | On Dec. 16, the U.S. Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Vraylar the go-ahead as an adjunctive (add-on) treatment for patients with major depressive disorder (MDD).
What was the clinical data behind the FDA's decision to award Vraylar with its fourth indication? And what could this news mean f... | On Dec. 16, the U.S. Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Vraylar the go-ahead as an adjunctive (add-on) treatment for patients with major depressive disorder (MDD). As more new drugs are launched and the initial brunt of the revenue decline from Humira is absorbed, AbbVie should return to soli... | Thus, the MDD indication for Vraylar could add $400 million in annual revenue for AbbVie. On Dec. 16, the U.S. Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Vraylar the go-ahead as an adjunctive (add-on) treatment for patients with major depressive disorder (MDD). But how much of a difference could it m... | On Dec. 16, the U.S. Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Vraylar the go-ahead as an adjunctive (add-on) treatment for patients with major depressive disorder (MDD). But how much of a difference could it make for AbbVie's top line? Thus, the MDD indication for Vraylar could add $400 million in ... | On Dec. 16, the U.S. Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Vraylar the go-ahead as an adjunctive (add-on) treatment for patients with major depressive disorder (MDD). Thus, the MDD indication for Vraylar could add $400 million in annual revenue for AbbVie. But how much of a difference could it m... |
22,872 | 2023-01-17 00:00:00 UTC | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-dips-more-than-broader-markets%3A-what-you-should-know-1 | null | null | AbbVie (ABBV) closed at $152.83 in the latest trading session, marking a -0.5% move from the prior day. This change lagged the S&P 500's 0.2% loss on the day. At the same time, the Dow lost 1.14%, and the tech-heavy Nasdaq gained 1.39%.
Heading into today, shares of the drugmaker had lost 4.89% over the past month, lag... | AbbVie (ABBV) closed at $152.83 in the latest trading session, marking a -0.5% move from the prior day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.67 per share, which would represent year-over-year grow... | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed at $152.83 in the latest trading session, marking a -0.5% move from the prior day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings re... | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed at $152.83 in the latest trading session, marking a -0.5% move from the prior day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings re... | AbbVie (ABBV) closed at $152.83 in the latest trading session, marking a -0.5% move from the prior day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.67 per share, which would represent year-over-year grow... |
22,873 | 2023-01-17 00:00:00 UTC | This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich | ABBV | https://www.nasdaq.com/articles/this-monumental-breakthrough-could-turn-the-world-upside-down-and-make-some-investors | null | null | You might have heard the stories about Ponce de Leon's search for the fountain of youth. As it turns out, there's no evidence that the Spanish explorer actually embarked on such a search. The stories appear to be as mythical as the fountain of youth itself.
But the idea of restoring youth could be about to move from my... | It teamed up with AbbVie (NYSE: ABBV) to develop new therapies for age-related diseases. The two big partners are likely closely watching the latest developments, especially considering that AbbVie already has epigenetics programs underway. Keith Speights has positions in AbbVie and Alphabet. | It teamed up with AbbVie (NYSE: ABBV) to develop new therapies for age-related diseases. The two big partners are likely closely watching the latest developments, especially considering that AbbVie already has epigenetics programs underway. Keith Speights has positions in AbbVie and Alphabet. | It teamed up with AbbVie (NYSE: ABBV) to develop new therapies for age-related diseases. The two big partners are likely closely watching the latest developments, especially considering that AbbVie already has epigenetics programs underway. Keith Speights has positions in AbbVie and Alphabet. | It teamed up with AbbVie (NYSE: ABBV) to develop new therapies for age-related diseases. The two big partners are likely closely watching the latest developments, especially considering that AbbVie already has epigenetics programs underway. Keith Speights has positions in AbbVie and Alphabet. |
22,874 | 2023-01-17 00:00:00 UTC | Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)? | ABBV | https://www.nasdaq.com/articles/should-you-invest-in-the-invesco-dynamic-pharmaceuticals-etf-pjp-5 | null | null | Launched on 06/23/2005, the Invesco Dynamic Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs,... | Looking at individual holdings, Pfizer Inc (PFE) accounts for about 6.84% of total assets, followed by Merck & Co Inc (MRK) and Abbvie Inc (ABBV). Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free S... | Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceut... | Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceut... | Looking at individual holdings, Pfizer Inc (PFE) accounts for about 6.84% of total assets, followed by Merck & Co Inc (MRK) and Abbvie Inc (ABBV). Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free S... |
22,875 | 2023-01-17 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-61 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Medtronic PLC (Symbol: MDT) $80.59 $87.29 8.32% Nordson Corp. (Symbol: NDSN) $243.84 $263.17 7.93% AbbVie Inc (Symbol: ABBV) $153.60 $164.57 7.14% PepsiCo Inc (Symbol: PEP) $175.24 $186.93 6.67% RenaissanceRe Holdings Ltd. (Symbol: RNR) $198.25 $211.25 6.56% The average 12-month analyst targets are only targets for the... | Medtronic PLC (Symbol: MDT) $80.59 $87.29 8.32% Nordson Corp. (Symbol: NDSN) $243.84 $263.17 7.93% AbbVie Inc (Symbol: ABBV) $153.60 $164.57 7.14% PepsiCo Inc (Symbol: PEP) $175.24 $186.93 6.67% RenaissanceRe Holdings Ltd. (Symbol: RNR) $198.25 $211.25 6.56% The average 12-month analyst targets are only targets for the... | Medtronic PLC (Symbol: MDT) $80.59 $87.29 8.32% Nordson Corp. (Symbol: NDSN) $243.84 $263.17 7.93% AbbVie Inc (Symbol: ABBV) $153.60 $164.57 7.14% PepsiCo Inc (Symbol: PEP) $175.24 $186.93 6.67% RenaissanceRe Holdings Ltd. (Symbol: RNR) $198.25 $211.25 6.56% The average 12-month analyst targets are only targets for the... | Medtronic PLC (Symbol: MDT) $80.59 $87.29 8.32% Nordson Corp. (Symbol: NDSN) $243.84 $263.17 7.93% AbbVie Inc (Symbol: ABBV) $153.60 $164.57 7.14% PepsiCo Inc (Symbol: PEP) $175.24 $186.93 6.67% RenaissanceRe Holdings Ltd. (Symbol: RNR) $198.25 $211.25 6.56% The average 12-month analyst targets are only targets for the... |
22,876 | 2023-01-16 00:00:00 UTC | Pick Either Merck Stock Or Its Peer – Both May Offer Similar Returns | ABBV | https://www.nasdaq.com/articles/pick-either-merck-stock-or-its-peer-both-may-offer-similar-returns | null | null | We believe that pharmaceutical giants Merck stock (NYSE: MRK) and Pfizer stock (NYSE: PFE) will likely offer similar returns over the next three years. Although Merck is trading at a comparatively higher valuation of 4.9x trailing revenues vs.2.9x for Pfizer, this valuation gap can be attributed to Merck’s lower financ... | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Merck vs. Pfizer: Which Stock Is A Better Bet? Merck, over the recent years, has benefited from the label expansion of Keytruda and strong demand for vaccines, primarily Gardasil. Beyond the ... | We believe that pharmaceutical giants Merck stock (NYSE: MRK) and Pfizer stock (NYSE: PFE) will likely offer similar returns over the next three years. However, if we look at a longer time frame, Pfizer saw its revenue grow at an average annual rate of 32.2% to $81.3 billion in 2021, compared to $40.8 billion in 2018, ... | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Merck vs. Pfizer: Which Stock Is A Better Bet? However, if we look at a longer time frame, Pfizer saw its revenue grow at an average annual rate of 32.2% to $81.3 billion in 2021, compared to... | For companies registering positive revenue growth during Covid, we consider yearly average growth before Covid with a certain weight to growth during Covid and the last twelve months. Pfizer Is More Profitable But Comes At Higher Risk Merck’s operating margin of 30.7% over the last twelve-month period is slightly lower... |
22,877 | 2023-01-16 00:00:00 UTC | BioMed X Extends Research Collaboration With AbbVie On Immunology And Tissue Engineering | ABBV | https://www.nasdaq.com/articles/biomed-x-extends-research-collaboration-with-abbvie-on-immunology-and-tissue-engineering | null | null | (RTTNews) - BioMed X, an independent German biomedical research institute, said that it has extended its ongoing research collaboration with AbbVie (ABBV). This marks the launch of the first BioMed X Institute in the US, to be located in New Haven, Connecticut.
BioMed X noted that the new US-based research collaboratio... | (RTTNews) - BioMed X, an independent German biomedical research institute, said that it has extended its ongoing research collaboration with AbbVie (ABBV). The current partnership with AbbVie is focused on the development of a new tissue engineering platform to produce complex human ex vivo models (disease-on-a-chip) f... | (RTTNews) - BioMed X, an independent German biomedical research institute, said that it has extended its ongoing research collaboration with AbbVie (ABBV). The current partnership with AbbVie is focused on the development of a new tissue engineering platform to produce complex human ex vivo models (disease-on-a-chip) f... | The current partnership with AbbVie is focused on the development of a new tissue engineering platform to produce complex human ex vivo models (disease-on-a-chip) from primary human cells and tissues to study human tissue inflammation. (RTTNews) - BioMed X, an independent German biomedical research institute, said that... | (RTTNews) - BioMed X, an independent German biomedical research institute, said that it has extended its ongoing research collaboration with AbbVie (ABBV). The current partnership with AbbVie is focused on the development of a new tissue engineering platform to produce complex human ex vivo models (disease-on-a-chip) f... |
22,878 | 2023-01-16 00:00:00 UTC | 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income | ABBV | https://www.nasdaq.com/articles/3-top-ranked-dividend-stocks%3A-a-smarter-way-to-boost-your-retirement-income-47 | null | null | Here's an eye-opening statistic: older Americans are more afraid of running out of money than of death itself.
And older Americans have legitimate reasons for this worry, even if they have dutifully saved for their golden years. That's because the traditional ways people manage retirement may no longer provide enough i... | AbbVie (ABBV) is currently shelling out a dividend of $1.48 per share, with a dividend yield of 3.85%. Check AbbVie (ABBV) dividend history here>>> The Bank of New York Mellon Corporation (BK) is paying out a dividend of $0.37 per share at the moment, with a dividend yield of 3.02% compared to the Banks - Major Regiona... | Check AbbVie (ABBV) dividend history here>>> The Bank of New York Mellon Corporation (BK) is paying out a dividend of $0.37 per share at the moment, with a dividend yield of 3.02% compared to the Banks - Major Regional industry's yield of 3.21% and the S&P 500's yield. Click to get this free report AbbVie Inc. (ABBV) :... | Check AbbVie (ABBV) dividend history here>>> The Bank of New York Mellon Corporation (BK) is paying out a dividend of $0.37 per share at the moment, with a dividend yield of 3.02% compared to the Banks - Major Regional industry's yield of 3.21% and the S&P 500's yield. AbbVie (ABBV) is currently shelling out a dividend... | AbbVie (ABBV) is currently shelling out a dividend of $1.48 per share, with a dividend yield of 3.85%. Check AbbVie (ABBV) dividend history here>>> The Bank of New York Mellon Corporation (BK) is paying out a dividend of $0.37 per share at the moment, with a dividend yield of 3.02% compared to the Banks - Major Regiona... |
22,879 | 2023-01-16 00:00:00 UTC | 5 Dividend Kings I Bought for My Portfolio | ABBV | https://www.nasdaq.com/articles/5-dividend-kings-i-bought-for-my-portfolio | null | null | In periods of rising inflation and slowing economic growth, one constant investors can count on is the reliability of dividend stocks to see them through.
The asset managers at Hartford Funds looked at the performance of the benchmark S&P 500 going all the way back to 1930 and found that dividends contributed 40% to th... | AbbVie Even though pharmaceutical stock AbbVie (NYSE: ABBV) was only spun off from Abbott Laboratories in 2013, it is considered a Dividend King anyway because it is credited with the dividend history of its former parent, which began hiking the payout in 1972. AbbVie has continued that tradition -- increasing its quar... | See the 10 stocks *Stock Advisor returns as of January 9, 2023 Rich Duprey has positions in AbbVie, American States Water, Kimberly Clark, Lowe's Companies, and PPG Industries. AbbVie Even though pharmaceutical stock AbbVie (NYSE: ABBV) was only spun off from Abbott Laboratories in 2013, it is considered a Dividend Kin... | AbbVie Even though pharmaceutical stock AbbVie (NYSE: ABBV) was only spun off from Abbott Laboratories in 2013, it is considered a Dividend King anyway because it is credited with the dividend history of its former parent, which began hiking the payout in 1972. AbbVie has continued that tradition -- increasing its quar... | See the 10 stocks *Stock Advisor returns as of January 9, 2023 Rich Duprey has positions in AbbVie, American States Water, Kimberly Clark, Lowe's Companies, and PPG Industries. AbbVie Even though pharmaceutical stock AbbVie (NYSE: ABBV) was only spun off from Abbott Laboratories in 2013, it is considered a Dividend Kin... |
22,880 | 2023-01-16 00:00:00 UTC | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar-4 | null | null | Looking for broad exposure to the Large Cap Value segment of the US equity market? You should consider the First Trust Morningstar Dividend Leaders ETF (FDL), a passively managed exchange traded fund launched on 03/09/2006.
The fund is sponsored by First Trust Advisors. It has amassed assets over $5.04 billion, making ... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 10.41% of total assets, followed by Verizon Communications Inc. (VZ) and Abbvie Inc. (ABBV). Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock ... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 10.41% of total assets, followed by Verizon Communications Inc. (VZ) and Abbvie Inc. (ABBV). Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock ... | Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Verizon Communications Inc. (VZ) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Research Reports i... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 10.41% of total assets, followed by Verizon Communications Inc. (VZ) and Abbvie Inc. (ABBV). Click to get this free report First Trust Morningstar Dividend Leaders ETF (FDL): ETF Research Reports Exxon Mobil Corporation (XOM) : Free Stock ... |
22,881 | 2023-01-16 00:00:00 UTC | AbbVie, Eli Lilly exit UK drug pricing agreement | ABBV | https://www.nasdaq.com/articles/abbvie-eli-lilly-exit-uk-drug-pricing-agreement-0 | null | null | Adds details, background
Jan 16 (Reuters) - Pharmaceutical companies AbbVie ABBV.N and Eli Lilly LLY.N have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday.
Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global b... | Adds details, background Jan 16 (Reuters) - Pharmaceutical companies AbbVie ABBV.N and Eli Lilly LLY.N have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global b... | Adds details, background Jan 16 (Reuters) - Pharmaceutical companies AbbVie ABBV.N and Eli Lilly LLY.N have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global b... | Adds details, background Jan 16 (Reuters) - Pharmaceutical companies AbbVie ABBV.N and Eli Lilly LLY.N have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global b... | Adds details, background Jan 16 (Reuters) - Pharmaceutical companies AbbVie ABBV.N and Eli Lilly LLY.N have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global b... |
22,882 | 2023-01-16 00:00:00 UTC | AbbVie, Eli Lilly exit UK drug pricing agreement | ABBV | https://www.nasdaq.com/articles/abbvie-eli-lilly-exit-uk-drug-pricing-agreement | null | null | Jan 16 (Reuters) - Pharmaceutical companies AbbVie ABBV.N and Eli Lilly LLY.N have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday.
Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors a... | Jan 16 (Reuters) - Pharmaceutical companies AbbVie ABBV.N and Eli Lilly LLY.N have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors a... | Jan 16 (Reuters) - Pharmaceutical companies AbbVie ABBV.N and Eli Lilly LLY.N have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors a... | Jan 16 (Reuters) - Pharmaceutical companies AbbVie ABBV.N and Eli Lilly LLY.N have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors a... | Jan 16 (Reuters) - Pharmaceutical companies AbbVie ABBV.N and Eli Lilly LLY.N have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors a... |
22,883 | 2023-01-13 00:00:00 UTC | Want to Get Richer? 3 Best Stocks to Buy Now and Hold Forever | ABBV | https://www.nasdaq.com/articles/want-to-get-richer-3-best-stocks-to-buy-now-and-hold-forever-0 | null | null | Some people chase significant, fast returns -- the get-rich-quick approach. But in reality, the steady effects of long-term compounding usually create life-changing wealth. Successful investing can be as simple as owning stocks of high-quality businesses that have grown consistently for many years.
Healthcare is a supe... | However, AbbVie has invested heavily in expanding its business recently, including acquiring Botox-owner Allergan for $63 billion and ramping up sales of emerging products like Rinvoq and Skyrizi. Mustering growth despite losing exclusivity for Humira underlines how wonderful a business AbbVie is and why investors can ... | An evolving pharmaceutical giant The pharmaceutical industry plays a massive role in the broader healthcare sector, and AbbVie (NYSE: ABBV) is one of the most prominent players in the field. It's been just over a decade since Abbott Laboratories spun off its pharmaceutical business as AbbVie, and the company has thrive... | An evolving pharmaceutical giant The pharmaceutical industry plays a massive role in the broader healthcare sector, and AbbVie (NYSE: ABBV) is one of the most prominent players in the field. It's been just over a decade since Abbott Laboratories spun off its pharmaceutical business as AbbVie, and the company has thrive... | An evolving pharmaceutical giant The pharmaceutical industry plays a massive role in the broader healthcare sector, and AbbVie (NYSE: ABBV) is one of the most prominent players in the field. It's been just over a decade since Abbott Laboratories spun off its pharmaceutical business as AbbVie, and the company has thrive... |
22,884 | 2023-01-13 00:00:00 UTC | FOCUS-Drug companies favor biotech meds over pills, citing new U.S. law | ABBV | https://www.nasdaq.com/articles/focus-drug-companies-favor-biotech-meds-over-pills-citing-new-u.s.-law | null | null | By Deena Beasley
San Francisco, Jan 13 (Reuters) - Drugmakers are prioritizing complex biotech medicines over treatments that can be given as pills because recent U.S. legislation gives biologics a longer runway before becoming subject to government price limits, top industry executives said this week.
The Inflation Re... | These biologics, like AbbVie's ABBV.N rheumatoid arthritis drug Humira, need to be injected or infused and can require special handling or monitoring of patients. By Deena Beasley San Francisco, Jan 13 (Reuters) - Drugmakers are prioritizing complex biotech medicines over treatments that can be given as pills because r... | These biologics, like AbbVie's ABBV.N rheumatoid arthritis drug Humira, need to be injected or infused and can require special handling or monitoring of patients. By Deena Beasley San Francisco, Jan 13 (Reuters) - Drugmakers are prioritizing complex biotech medicines over treatments that can be given as pills because r... | These biologics, like AbbVie's ABBV.N rheumatoid arthritis drug Humira, need to be injected or infused and can require special handling or monitoring of patients. The law sets a nine-year exemption period for "small-molecule" drugs, which are mainly pills, while "large molecule" biologics, generally injections or infus... | These biologics, like AbbVie's ABBV.N rheumatoid arthritis drug Humira, need to be injected or infused and can require special handling or monitoring of patients. By Deena Beasley San Francisco, Jan 13 (Reuters) - Drugmakers are prioritizing complex biotech medicines over treatments that can be given as pills because r... |
22,885 | 2023-01-12 00:00:00 UTC | ABBV March 3rd Options Begin Trading | ABBV | https://www.nasdaq.com/articles/abbv-march-3rd-options-begin-trading | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the March 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new March 3rd contracts and identified one put and one call contract of particular interest.
The put contract a... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $155.00 strike highlighted in red: Considering the fact that the $155.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $150.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $155.00 strike price has a current bid of $4.90. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new March 3rd contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $155.00 strike highlighted in red: Consideri... |
22,886 | 2023-01-12 00:00:00 UTC | Zacks Market Edge Highlights: EXAS, ZM, TSLA, ABBV, ZOM | ABBV | https://www.nasdaq.com/articles/zacks-market-edge-highlights%3A-exas-zm-tsla-abbv-zom | null | null | For Immediate Release
Chicago, IL – January 12, 2023 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
h... | AbbVie (ABBV) AbbVie is a top 10 holding in the JPMorgan Equity Premium ETF. AbbVie is paying a dividend yielding 3.5%. Is the rally in AbbVie done? | Click to get this free report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Zoom Video Communications, Inc. (ZM) : Free Stock Analysis Report To rea... | Click to get this free report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Zoom Video Communications, Inc. (ZM) : Free Stock Analysis Report To rea... | AbbVie (ABBV) AbbVie is a top 10 holding in the JPMorgan Equity Premium ETF. AbbVie is paying a dividend yielding 3.5%. Is the rally in AbbVie done? |
22,887 | 2023-01-12 00:00:00 UTC | Notable Thursday Option Activity: IAC, ABBV, RILY | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-iac-abbv-rily | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Iac Inc (Symbol: IAC), where a total volume of 11,137 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every... | Particularly high volume was seen for the $150 strike put option expiring January 20, 2023, with 2,195 contracts trading so far today, representing approximately 219,500 underlying shares of ABBV. Below is a chart showing IAC's trailing twelve month trading history, with the $55 strike highlighted in orange: AbbVie Inc... | Below is a chart showing IAC's trailing twelve month trading history, with the $55 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 49,851 contracts thus far today. Below is a chart showing ABBV's trailing twelve month trading history, with the $150 strike highlighted in orange: A... | Below is a chart showing ABBV's trailing twelve month trading history, with the $150 strike highlighted in orange: And B. Riley Financial Inc (Symbol: RILY) saw options trading volume of 5,207 contracts, representing approximately 520,700 underlying shares or approximately 92.7% of RILY's average daily trading volume o... | Particularly high volume was seen for the $150 strike put option expiring January 20, 2023, with 2,195 contracts trading so far today, representing approximately 219,500 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $150 strike highlighted in orange: And B. R... |
22,888 | 2023-01-11 00:00:00 UTC | 1 Hot Growth Stock to Buy Now, and 1 to Avoid | ABBV | https://www.nasdaq.com/articles/1-hot-growth-stock-to-buy-now-and-1-to-avoid | null | null | Discerning between popular growth stocks that have room to run and those that will leave your portfolio in the red isn't an easy task, especially for companies in the biopharma sector. Picking the businesses that have the right mix of reliable earnings and catalysts for growth is key, but it takes more than a drug appr... | 1 to buy: AbbVie AbbVie (NYSE: ABBV) is a pharmaceutical growth stock par excellence because it will be commercializing new medicines and expanding the prescribable indications of its existing set of medicines at a quick clip throughout the rest of the decade. The anticipated loss of exclusivity protections for Humira ... | 1 to buy: AbbVie AbbVie (NYSE: ABBV) is a pharmaceutical growth stock par excellence because it will be commercializing new medicines and expanding the prescribable indications of its existing set of medicines at a quick clip throughout the rest of the decade. The anticipated loss of exclusivity protections for Humira ... | 1 to buy: AbbVie AbbVie (NYSE: ABBV) is a pharmaceutical growth stock par excellence because it will be commercializing new medicines and expanding the prescribable indications of its existing set of medicines at a quick clip throughout the rest of the decade. 10 stocks we like better than AbbVie When our award-winning... | 1 to buy: AbbVie AbbVie (NYSE: ABBV) is a pharmaceutical growth stock par excellence because it will be commercializing new medicines and expanding the prescribable indications of its existing set of medicines at a quick clip throughout the rest of the decade. The anticipated loss of exclusivity protections for Humira ... |
22,889 | 2023-01-11 00:00:00 UTC | The Stocks Behind 2022's Popular ETFs | ABBV | https://www.nasdaq.com/articles/the-stocks-behind-2022s-popular-etfs | null | null | (0:45) - Breaking Down Fund Flows For 2022: Should You Be Buying Back Into Cathie Wood?
(5:15) - What Is Cathie Wood Currently Buying?
(14:05) - Income ETFs On The Rise: Should You Be Adding Exposure To Your Portfolio?
(22:50) - Will The Energy Sector Continue To Outperform?
(32:30) - Episode Roundup: ARKK, SCHD, JEPI,... | AbbVie ABBV AbbVie is a top 10 holding in the JPMorgan Equity Premium ETF. AbbVie is paying a dividend yielding 3.5%. Is the rally in AbbVie done? | Click to get this free report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report ARK Innovation ETF (ARKK): ETF Research Reports Zoom Video Communication... | Click to get this free report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report ARK Innovation ETF (ARKK): ETF Research Reports Zoom Video Communication... | AbbVie ABBV AbbVie is a top 10 holding in the JPMorgan Equity Premium ETF. AbbVie is paying a dividend yielding 3.5%. Is the rally in AbbVie done? |
22,890 | 2023-01-11 00:00:00 UTC | 3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off | ABBV | https://www.nasdaq.com/articles/3-supercharged-dividend-stocks-to-buy-if-theres-a-stock-market-sell-off-4 | null | null | Choosing solid dividend stocks can be tricky. Buying a stock with a really high dividend yield is tempting, but many stocks with high dividends got that way because their share prices have plummeted. Often there's a genuine reason for declining shares, such as declining revenue or earnings.
Many stocks with high yields... | So, in looking for three healthcare stocks with supercharged dividends to buy in a market sell-off, it makes sense to look for companies that are strong enough to handle a down market while protecting their dividends -- companies such as Bristol-Myers Squibb (NYSE: BMY), AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbV... | So, in looking for three healthcare stocks with supercharged dividends to buy in a market sell-off, it makes sense to look for companies that are strong enough to handle a down market while protecting their dividends -- companies such as Bristol-Myers Squibb (NYSE: BMY), AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). Coun... | So, in looking for three healthcare stocks with supercharged dividends to buy in a market sell-off, it makes sense to look for companies that are strong enough to handle a down market while protecting their dividends -- companies such as Bristol-Myers Squibb (NYSE: BMY), AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). AbbV... | AbbVie continues to grow AbbVie is another company that easily shrugged off the share declines that affected other stocks in 2022, and it's up more than 19% during the past year. So, in looking for three healthcare stocks with supercharged dividends to buy in a market sell-off, it makes sense to look for companies that... |
22,891 | 2023-01-10 00:00:00 UTC | AbbVie, Anima Biotech Collaborate To Develop MRNA Modulators In Oncology, Immunology Targets | ABBV | https://www.nasdaq.com/articles/abbvie-anima-biotech-collaborate-to-develop-mrna-modulators-in-oncology-immunology-targets | null | null | (RTTNews) - AbbVie Inc. (ABBV), and Anima Biotech (Anima) Tuesday announced a collaboration in mRNA biology modulators for three targets across Oncology and Immunology. As per the agreement, Anima will receive an upfront payment of $42 million with the potential for further milestones and royalties and up to $540 milli... | The collaboration offers AbbVie exclusive rights to license and further develop and commercialize the programs. Jonathon Sedgwick, vice president and global head of discovery research of AbbVie said "Modulating mRNA biology with small molecules is a new approach and has the potential to address 'undruggable' targets wi... | (RTTNews) - AbbVie Inc. (ABBV), and Anima Biotech (Anima) Tuesday announced a collaboration in mRNA biology modulators for three targets across Oncology and Immunology. Jonathon Sedgwick, vice president and global head of discovery research of AbbVie said "Modulating mRNA biology with small molecules is a new approach ... | (RTTNews) - AbbVie Inc. (ABBV), and Anima Biotech (Anima) Tuesday announced a collaboration in mRNA biology modulators for three targets across Oncology and Immunology. Jonathon Sedgwick, vice president and global head of discovery research of AbbVie said "Modulating mRNA biology with small molecules is a new approach ... | The collaboration offers AbbVie exclusive rights to license and further develop and commercialize the programs. (RTTNews) - AbbVie Inc. (ABBV), and Anima Biotech (Anima) Tuesday announced a collaboration in mRNA biology modulators for three targets across Oncology and Immunology. Jonathon Sedgwick, vice president and g... |
22,892 | 2023-01-10 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-6 | null | null | AbbVie (ABBV) closed the most recent trading day at $159.64, moving -1.25% from the previous trading session. This move lagged the S&P 500's daily gain of 0.7%. Elsewhere, the Dow gained 0.56%, while the tech-heavy Nasdaq added 7.5%.
Heading into today, shares of the drugmaker had lost 2.21% over the past month, laggin... | AbbVie (ABBV) closed the most recent trading day at $159.64, moving -1.25% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release, which is expected to be February 9, 2023. In that report, analysts expect AbbVie to post earnings of $3.67 per share. | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed the most recent trading day at $159.64, moving -1.25% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release, whic... | AbbVie (ABBV) closed the most recent trading day at $159.64, moving -1.25% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release, which is expected to be February 9, 2023. In that report, analysts expect AbbVie to post earnings of $3.67 per share. | AbbVie (ABBV) closed the most recent trading day at $159.64, moving -1.25% from the previous trading session. AbbVie will be looking to display strength as it nears its next earnings release, which is expected to be February 9, 2023. In that report, analysts expect AbbVie to post earnings of $3.67 per share. |
22,893 | 2023-01-10 00:00:00 UTC | 3 Passive Income Stocks That Are Screaming Buys in January | ABBV | https://www.nasdaq.com/articles/3-passive-income-stocks-that-are-screaming-buys-in-january | null | null | After the bear market of 2022 slammed the share prices of most companies, now is a particularly opportune time to identify passive income stocks while they're cheap. There's no time like the present to build the foundations for tomorrow's wealth -- especially when it comes to stocks you could buy and hold for decades.
... | With profitability and such a fast tempo of new drug launches, AbbVie can afford to pay out plenty of money in dividends, and it's also fond of returning capital to shareholders via share repurchases. AbbVie Pharma company AbbVie (NYSE: ABBV) is a screaming buy because of its proven ability to keep commercializing new ... | AbbVie Pharma company AbbVie (NYSE: ABBV) is a screaming buy because of its proven ability to keep commercializing new medicines year after year. With profitability and such a fast tempo of new drug launches, AbbVie can afford to pay out plenty of money in dividends, and it's also fond of returning capital to sharehold... | AbbVie Pharma company AbbVie (NYSE: ABBV) is a screaming buy because of its proven ability to keep commercializing new medicines year after year. With profitability and such a fast tempo of new drug launches, AbbVie can afford to pay out plenty of money in dividends, and it's also fond of returning capital to sharehold... | * They just revealed what they believe are the ten best stocks for investors to buy right now… and AbbVie wasn't one of them! AbbVie Pharma company AbbVie (NYSE: ABBV) is a screaming buy because of its proven ability to keep commercializing new medicines year after year. With profitability and such a fast tempo of new ... |
22,894 | 2023-01-10 00:00:00 UTC | Ex-Dividend Reminder: Buckle, Foot Locker and AbbVie | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-buckle-foot-locker-and-abbvie | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 1/12/23, Buckle, Inc. (Symbol: BKE), Foot Locker, Inc. (Symbol: FL), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. will pay its quarterly dividend of $0.35 on 1/27/23, Foot Locker, Inc. wi... | If they do continue, the current estimated yields on annualized basis would be 2.89% for Buckle, Inc., 4.07% for Foot Locker, Inc., and 3.71% for AbbVie Inc. Looking at the universe of stocks we cover at Dividend Channel, on 1/12/23, Buckle, Inc. (Symbol: BKE), Foot Locker, Inc. (Symbol: FL), and AbbVie Inc (Symbol: AB... | Looking at the universe of stocks we cover at Dividend Channel, on 1/12/23, Buckle, Inc. (Symbol: BKE), Foot Locker, Inc. (Symbol: FL), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. will pay its quarterly dividend of $0.35 on 1/27/23, Foot Locker, Inc. wi... | Looking at the universe of stocks we cover at Dividend Channel, on 1/12/23, Buckle, Inc. (Symbol: BKE), Foot Locker, Inc. (Symbol: FL), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. will pay its quarterly dividend of $0.35 on 1/27/23, Foot Locker, Inc. wi... | If they do continue, the current estimated yields on annualized basis would be 2.89% for Buckle, Inc., 4.07% for Foot Locker, Inc., and 3.71% for AbbVie Inc. Looking at the universe of stocks we cover at Dividend Channel, on 1/12/23, Buckle, Inc. (Symbol: BKE), Foot Locker, Inc. (Symbol: FL), and AbbVie Inc (Symbol: AB... |
22,895 | 2023-01-10 00:00:00 UTC | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-attracting-investor-attention%3A-here-is-what-you-should-know-3 | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -2.2% over the past month versus the Zacks S&P 500 composite's -0.9% chan... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie... | Last Reported Results and Surprise History AbbVie reported revenues of $14.81 billion in the last reported quarter, representing a year-over-year change of +3.3%. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has g... | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gained 0% over this period. For the current quarter, AbbVie is expected to post earnings of $3.67 per share, indicating a change of +10.9% from the year-ago quarter... | For the next fiscal year, the consensus earnings estimate of $11.70 indicates a change of -15.6% from what AbbVie is expected to report a year ago. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for AbbVie. Ab... |
22,896 | 2023-01-10 00:00:00 UTC | Should Investors Worry About AbbVie's Dividend? | ABBV | https://www.nasdaq.com/articles/should-investors-worry-about-abbvies-dividend | null | null | There's not much point in buying a passive-income stock like AbbVie (NYSE: ABBV) if it's going to fail to deliver its quarterly dividend into your account. Even reliable companies can sometimes run into problems that require them to level off or even slash their payment.
As it turns out, there is indeed a risk that wit... | In short, investors can have moderate to high confidence that AbbVie's dividend will continue to be a reliable source of passive income, and that's yet another factor making the stock an attractive purchase. There's not much point in buying a passive-income stock like AbbVie (NYSE: ABBV) if it's going to fail to delive... | Expect more payouts in the future Despite AbbVie's limited overhead for additional dividend hikes and its upcoming headwinds from the loss of Humira, it will probably be able to keep paying its dividend for the foreseeable future. There's not much point in buying a passive-income stock like AbbVie (NYSE: ABBV) if it's ... | Competitors like Bristol-Myers Squibb, Sanofi, and Johnson & Johnson all have payout ratios above 60%, so AbbVie is hardly alone in having a somewhat limited overhead to keep hiking dividends in the absence of earnings growth. Expect more payouts in the future Despite AbbVie's limited overhead for additional dividend h... | Expect more payouts in the future Despite AbbVie's limited overhead for additional dividend hikes and its upcoming headwinds from the loss of Humira, it will probably be able to keep paying its dividend for the foreseeable future. * They just revealed what they believe are the ten best stocks for investors to buy right... |
22,897 | 2023-01-10 00:00:00 UTC | Abbvie raises sales outlook of two new drugs to more than $17.5 bln in 2025 | ABBV | https://www.nasdaq.com/articles/abbvie-raises-sales-outlook-of-two-new-drugs-to-more-than-%2417.5-bln-in-2025 | null | null | Adds background
Jan 10 (Reuters) - AbbVie Inc ABBV.N on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira.
The company's previous sales outlook for Skyrizi an... | Adds background Jan 10 (Reuters) - AbbVie Inc ABBV.N on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira. AbbVie also expects peak sales of the drugs to exce... | Adds background Jan 10 (Reuters) - AbbVie Inc ABBV.N on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira. AbbVie also expects peak sales of the drugs to exce... | Adds background Jan 10 (Reuters) - AbbVie Inc ABBV.N on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira. AbbVie also expects peak sales of the drugs to exce... | Adds background Jan 10 (Reuters) - AbbVie Inc ABBV.N on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira. AbbVie also expects peak sales of the drugs to exce... |
22,898 | 2023-01-09 00:00:00 UTC | AbbVie's Qulipta Approved In Canada For Preventive Treatment Of Episodic Migraine In Adults | ABBV | https://www.nasdaq.com/articles/abbvies-qulipta-approved-in-canada-for-preventive-treatment-of-episodic-migraine-in-adults | null | null | (RTTNews) - AbbVie (ABBV) said that Health Canada has approved Qulipta (atogepant) for the prevention of episodic migraine (less than 15 migraine days per month) in adults.
The approval is supported by data from a robust clinical program evaluating the efficacy, safety and tolerability of Qulipta in nearly 2,000 patien... | (RTTNews) - AbbVie (ABBV) said that Health Canada has approved Qulipta (atogepant) for the prevention of episodic migraine (less than 15 migraine days per month) in adults. The approval is supported by data from a robust clinical program evaluating the efficacy, safety and tolerability of Qulipta in nearly 2,000 patien... | (RTTNews) - AbbVie (ABBV) said that Health Canada has approved Qulipta (atogepant) for the prevention of episodic migraine (less than 15 migraine days per month) in adults. Qulipta (atogepant) is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist specifically developed for the preventive... | (RTTNews) - AbbVie (ABBV) said that Health Canada has approved Qulipta (atogepant) for the prevention of episodic migraine (less than 15 migraine days per month) in adults. Qulipta demonstrated statistically significant, clinically meaningful, rapid and continuous reductions in mean monthly migraine days among adults w... | (RTTNews) - AbbVie (ABBV) said that Health Canada has approved Qulipta (atogepant) for the prevention of episodic migraine (less than 15 migraine days per month) in adults. Qulipta demonstrated statistically significant, clinically meaningful, rapid and continuous reductions in mean monthly migraine days among adults w... |
22,899 | 2023-01-09 00:00:00 UTC | Top Dividend Stocks To Invest In 2023? 3 For Your List | ABBV | https://www.nasdaq.com/articles/top-dividend-stocks-to-invest-in-2023-3-for-your-list | null | null | A dividend stock is a type of stock that pays out a portion of the company’s profits to shareholders in the form of dividends. These payments are generally paid on a regular basis. This can include quarterly or annually. While dividends are typically paid in cash. Although they can also be paid in the form of additiona... | Considering this, here are three top dividend stocks to watch in the stock market in 2023. Dividend Stocks To Watch For 2023 The McDonald’s Corporation (NYSE: MCD) AbbVie Inc. (NYSE: ABBV) United Parcel Service Inc. (NYSE: UPS) McDonald’s Corporation (MCD Stock) Leading off, McDonald’s Corporation (MCD) is a multinatio... | Considering this, here are three top dividend stocks to watch in the stock market in 2023. Dividend Stocks To Watch For 2023 The McDonald’s Corporation (NYSE: MCD) AbbVie Inc. (NYSE: ABBV) United Parcel Service Inc. (NYSE: UPS) McDonald’s Corporation (MCD Stock) Leading off, McDonald’s Corporation (MCD) is a multinatio... | Considering this, here are three top dividend stocks to watch in the stock market in 2023. Dividend Stocks To Watch For 2023 The McDonald’s Corporation (NYSE: MCD) AbbVie Inc. (NYSE: ABBV) United Parcel Service Inc. (NYSE: UPS) McDonald’s Corporation (MCD Stock) Leading off, McDonald’s Corporation (MCD) is a multinatio... | Considering this, here are three top dividend stocks to watch in the stock market in 2023. Dividend Stocks To Watch For 2023 The McDonald’s Corporation (NYSE: MCD) AbbVie Inc. (NYSE: ABBV) United Parcel Service Inc. (NYSE: UPS) McDonald’s Corporation (MCD Stock) Leading off, McDonald’s Corporation (MCD) is a multinatio... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.